$SVRA Issuance Of U.S. Composition Of Matter Patent Covering AeroVanc

AUSTIN, Texas, May 8, 2017  — Savara Inc. (NASDAQ: SVRA), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases, today announced the recent issuance of United States Patent No. 9,572,774 for “Dry Powder Vancomycin Compositions and Associated Methods” by the United States Patent and Trademark Office. The patent will provide key intellectual property protection in the U.S. for the AeroVanc program and will expire no earlier than 2032.  This affords Savara important composition of matter protection for its AeroVanc program in the U.S., the largest market for the product, and is a key component of the Company’s market protection strategy which also includes Orphan Drug and Qualified Infectious Disease Product protection.

Savara has also received a Notice of Allowance from the Canadian Intellectual Property Office for its Canadian Patent Application No. 2,836,643 entitled “Dry Powder Vancomycin Compositions and Associated Methods.” This notice serves as official communication that the examination of the patent application has been successfully completed. Once issued, the patent will provide protection for AeroVanc in Canada until 2032. The Company also has corresponding patent applications for AeroVanc in different stages of prosecution in other key markets throughout the world.

About AeroVanc

The prevalence of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection in cystic fibrosis (CF) patients has continued to rise in the United States, and the infection has been associated with increased use of intravenous, or IV, antibiotics, increased hospitalizations, a faster decline of lung function, as well as shortened life-expectancy. Despite inhaled antibiotics being available to CF patients for over ten years to treat non-MRSA infections, there is no approved inhaled antibiotic for the treatment of MRSA in CF. AeroVanc is being developed to address this unmet medical need in CF.

In a randomized, double-blind, placebo-controlled Phase 2 study in CF patients with persistent MRSA infection, AeroVanc reduced MRSA density in sputum, and showed encouraging trends of improvement in lung function, and respiratory symptoms, as well as prolongation of the time to use of other antibiotics, with best responses in subjects under 21 years of age. Savara plans to initiate a pivotal Phase 3 study of AeroVanc for the treatment of MRSA in CF patients in the third quarter of 2017.

AeroVanc has been granted Orphan Drug Designation and Qualified Infectious Disease Product, or QIDP, status for the treatment of persistent MRSA lung infection in CF patients in the United States. The Orphan Drug Designation makes AeroVanc eligible for seven years of exclusivity from approval in the United States, and ten years of exclusivity in the European Union and the QIDP designation makes AeroVanc eligible for an additional five years of exclusivity in the United States.

About Savara

Savara Inc. is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Savara’s pipeline comprises AeroVanc, a Phase 3 ready inhaled vancomycin, Molgradex, a Phase 2/3 stage inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF and Aironite, an inhaled nebulized sodium nitrite solution to treat HFpEF. Savara’s strategy involves expanding its pipeline of best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, in identifying unmet needs, creating and acquiring new product candidates, and effectively advancing them to approvals and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma)

Forward Looking Statements

Savara cautions you that statements in this press release that are not a description of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as “expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,” among others. Such statements include, but are not limited to, statements regarding the potential future benefits of patent protection, the impact of AeroVanc use, the timing of our AeroVanc Phase 3 study and Savara’s strategy and goals. Savara may not actually achieve any of the matters referred to in such forward looking statements, and you should not place undue reliance on these forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Savara’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the results and actual timing of clinical studies for our product candidates, our actual ability to protect our patented technology, the availability of sufficient resources for Savara’s operations and to conduct or continue planned clinical development programs, the timing and ability of Savara to raise additional equity capital to fund continued operations; the ability to successfully develop Savara’s product candidates, and the risks associated with the process of developing, obtaining regulatory approval for and commercializing drug candidates that are safe and effective for use as human therapeutics. Risks and uncertainties facing Savara are described more fully in Savara’s filings with the Securities and Exchange Commission including the Form 8-K filed on April 27, 2017, other filings on Form 8-K, the Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and the Registration Statement on Form S-4 related to the Mast/Savara merger. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Savara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.

$NYMX Files On First In Class Prostate Drug in Europe; Teleconference May 10

HASBROUCK HEIGHTS, N.J., May 08, 2017 — Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Following Nymox’s announcement of the Company’s filing for marketing approval of Fexapotide Triflutate for enlarged prostate (BPH) in Europe, Nymox is pleased to announce a teleconference with shareholders at 4:30 p.m. EDT on Wednesday May 10, 2017. The call-in number will be reported prior to the teleconference call.

Shareholder questions in advance are welcomed and can be sent by email to: info@nymox.com

Forward Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox’s regulatory filings, Nymox’s substantial dependence on fexapotide, Nymox’s commercialization plans and efforts and other matters that could affect the availability or commercial potential of fexapotide. Nymox undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox’s current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2016, and its Quarterly Reports.

Contact:
Paul Averback
Nymox Pharmaceutical Corporation
800-93NYMOX
www.nymox.com

$STRP Bidding War Continues, $184.00 Share Price Leads Pack

Straight Path Communications Inc. (“Straight Path”) (NYSE MKT:STRP) announced today that the Straight Path Board of Directors (the “Straight Path Board”) determined that a revised offer from a multi-national telecommunications company (the “Bidder”) to acquire 100% of the issued and outstanding shares of Straight Path for $184.00 per share (reflecting an enterprise value of approximately $3.1 billion), which will be paid in Bidder stock in an all-stock transaction constitutes a “Superior Proposal” as defined in Straight Path’s previously announced definitive agreement and plan of merger with AT&T Inc. (“AT&T”) (NYSE: T) and Switchback Merger Sub Inc., dated as of April 9, 2017 (the “AT&T Merger Agreement”). The Bidder previously submitted an unsolicited offer on May 1, 2017 to acquire 100% of the issued and outstanding shares of Straight Path for $135.96 per share (reflecting an enterprise value of $2.3 billion), which has been superseded by the revised offer announced today.

Under the terms of the AT&T Merger Agreement, AT&T agreed to acquire Straight Path in an all-stock transaction in which Straight Path stockholders would receive $95.63 per share (reflecting an enterprise value of $1.6 billion), which would be paid using AT&T stock.

Straight Path has notified AT&T of the Straight Path Board’s determination and, pursuant to the AT&T Merger Agreement, AT&T has the option for the next three (3) business days (the “Negotiation Period”) to negotiate a possible amendment of that agreement to match or exceed the Bidder’s offer. Straight Path is required, and intends to, negotiate in good faith with AT&T during the Negotiation Period. Straight Path is not permitted to enter into the Bidder’s merger agreement or to change its recommendation in favor of the AT&T transaction unless, at the end of the Negotiation Period, the Straight Path Board determines that the Bidder’s offer continues to constitute a “Superior Proposal” and satisfies certain other requirements under the AT&T Merger Agreement. The Bidder has stated that its offer will remain outstanding until 11:59 p.m. New York City time on May 10, 2017.

Under the AT&T Merger Agreement, Straight Path is required to pay a $38 million termination fee to AT&T if the Straight Path Board terminates the AT&T Merger Agreement in order to enter into an agreement with the Bidder. The Bidder has agreed to pay the termination fee to AT&T on Straight Path’s behalf in such event. Straight Path would be required to repay the Bidder for the AT&T termination fee under certain circumstances in connection with a termination of the Bidder’s merger agreement.

At this time, Straight Path remains subject to the AT&T Merger Agreement and the Straight Path Board has not changed its recommendation in support of the AT&T transaction, the existing AT&T Merger Agreement, or its recommendation that Straight Path’s stockholders adopt the AT&T Merger Agreement. There can be no assurances that a transaction with the Bidder will result from the Bidder’s offer, or that any other transaction will be consummated. There can be no assurance that AT&T will seek to negotiate with Straight Path or will make a revised offer.

About Straight Path Communications Inc.
Straight Path (NYSE MKT: STRP) holds an extensive portfolio of 39 GHz and 28 GHz wireless spectrum licenses. Straight Path is developing next generation wireless technology through its Straight Path Ventures subsidiary. Straight Path holds licenses and conducts other business related to certain patents through its Straight Path IP Group subsidiary. Additional information is available on Straight Path’s websites.

Corporate: www.straightpath.com.
Spectrum: www.straightpath39.com.

IMPORTANT ADDITIONAL INFORMATION WILL BE FILED WITH THE SEC

Straight Path plans to file with the SEC and mail to its stockholders a Proxy Statement/Prospectus in connection with the proposed transaction. THE PROXY STATEMENT/PROSPECTUS WILL CONTAIN IMPORTANT INFORMATION ABOUT AT&T, STRAIGHT PATH, THE PROPOSED TRANSACTION AND RELATED MATTERS. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS CAREFULLY WHEN THEY BECOME AVAILABLE. Investors and security holders will be able to obtain free copies of the Proxy Statement/Prospectus and the other documents filed with the SEC by Straight Path through the web site maintained by the SEC at www.sec.gov. In addition, investors and security holders will be able to obtain free copies of the Proxy Statement/Prospectus by phone, e-mail or written request by contacting the investor relations department of Straight Path at the following:

PARTICIPANTS IN THE SOLICITATION

Straight Path and its directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of the proposed transactions contemplated by the AT&T Merger Agreement. Information regarding Straight Path’s directors and executive officers is contained in Straight Path’s Form 10-K for the year ended July 31, 2016 and its proxy statement dated November 22, 2016, which are filed with the SEC. A more complete description will be available in the Proxy Statement/Prospectus.

Safe Harbor

In this press release, all statements that are not purely about historical facts, including, but not limited to, those in which we use the words “believe,” “anticipate,” “expect,” “plan,” “intend,” “estimate, “target” and similar expressions, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. While these forward-looking statements represent our current judgment of what may happen in the future, actual results may differ materially from the results expressed or implied by these statements due to numerous important factors, including, but not limited to, those described in our Annual Report on Form 10-K for the fiscal year ended July 31, 2016 and our other periodic filings with the SEC (under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”). We are under no obligation, and expressly disclaim any obligation, to update the forward-looking statements in this press release, whether as a result of new information, future events or otherwise.

No Offer or Solicitation

This document does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

$AAPC and Cannabis Property REIT Kalyx Development, Business Combination

NEW YORK, May 8, 2017  — Atlantic Alliance Partnership Corp. (“AAPC”) (NASDAQ: AAPC) and Kalyx Development Inc., a private real estate investment trust focused on owning and operating commercial real estate facilities leased to cultivators, processors and/or distributors in the regulated U.S. cannabis industry (“Kalyx”), today announced that they have entered into a merger agreement under which, subject to certain closing conditions, Kalyx will merge with and into AAPC (the “Merger”).

With the terms of the Merger, AAPC attributed the current, pre-transaction value of Kalyx at approximately $60 million and a post-transaction market capitalization of approximately $75 million (subject to certain assumptions and variables).  The surviving public company, which is expected to be organized as a Maryland corporation, will be re-named Kalyx Properties Inc. (“KPI”).

Kalyx is a fully-integrated commercial real estate company which acquires and owns properties leased to, or currently occupied by, state-licensed operators of regulated cannabis businesses in states in which such activities are legal under state law.  Based in New York and operating as a private real estate investment trust, Kalyx owns and operates nine commercial properties comprising an aggregate of 653,000 square feet located in Arizona, Colorado, Oregon and Washington State and is one of the leading multistate providers of commercial real estate to state-licensed operators in the regulated cannabis industry.  Kalyx’s management team combines commercial real estate experience, cannabis industry expertise and a knowledge and understanding of the relevant state and local regulatory requirements that it leverages to source and acquire new commercial properties consistent with its strategy.

“We are excited about merging into AAPC and believe the transaction will provide Kalyx with an efficient path to a public listing on a U.S. stock exchange,” said George M. Stone, Kalyx’s Chief Executive Officer.  “Once this transaction is complete, we will have a stream-lined capital structure which will allow for regular access to public capital, thus enabling better-paced growth as well as the ability over time to attract institutional investors to strengthen and diversify KPI’s shareholder base.”

Iain H. Abrahams, Chief Executive Officer of AAPC, stated “Since meeting George Stone and the other members of the Kalyx management team, our team has been impressed with their grasp of the dynamics of the regulated U.S. cannabis industry and the needs of cannabis operator tenants.  We believe that giving the Kalyx team the ability to access public capital is the right way to build out the business and help Kalyx achieve its full potential.”

In connection with and as a condition to the closing of the Merger, AAPC expects to offer its common stock to accredited investors in a private placement (the “PIPE”).  As a further condition to the closing of the Merger, the proceeds of the PIPE, when combined with cash currently in AAPC’s trust account (subject to potential AAPC shareholder redemptions), will be required to equal or exceed $15 million in capital.  The new capital is anticipated to be used by KPI to make additional real estate acquisitions and for general working capital purposes.

Summary of Transaction

Pursuant to the Merger, all shareholders of Kalyx will receive shares of KPI based on AAPC’s aggregate pre-money equity valuation of Kalyx of approximately $60 million, with the shares to be issued by KPI being valued at $10 per share and holders of Kalyx warrants who do not elect to exchange such warrants for shares of Kalyx common stock (as described in the merger agreement) will have their warrants assumed by KPI (subject to a minimum threshold of such warrants being amended (as described in the merger agreement)).  AAPC shareholders who do not elect to redeem their AAPC ordinary shares will receive a stock dividend immediately prior to the closing based on the difference between the trust liquidation value per share at the closing of the Merger and the $10 per share price.  AAPC’s sponsor, AAP Sponsor (PTC) Corp, has agreed to forfeit a portion of the KPI shares that it would receive in the Merger for its founder shares.

Ellenoff Grossman & Schole LLP is serving as legal advisor to AAPC.  Sandler O’Neill + Partners, L.P. is serving as financial advisor, Reitler Kailas & Rosenblatt LLC as legal advisor and Dentons as REIT counsel to Kalyx.

The description of the Merger contained herein is only a summary and is qualified in its entirety by the reference to the definitive agreements relating to the transaction, copies of which will be filed by AAPC with the Securities and Exchange Commission in a Current Report on Form 8-K.

About Kalyx Development Inc.

Kalyx is a leading real estate investment trust in the regulated cannabis industry in the U.S. By retrofitting underutilized real estate assets, Kalyx accommodates the need of tenants in the cultivation, processing and/or distribution of cannabis and cannabis products. At the forefront of a new real estate vertical, Kalyx owns interests in nine properties totaling approximately 653,000 square feet in regulated cannabis markets within Colorado, Washington, Oregon and Arizona of which approximately 77% was occupied as of March 31, 2017.  Among Kalyx’s 23 tenants are many well established operators including Medicine Man, Dixie Brands, Golden Leaf, Health for Life and Strainwise.  Kalyx is not a cannabis operator.  It neither owns, nor does it intend to own, a financial interest in a cannabis business.

About AAPC

AAPC is a public investment vehicle incorporated in January 2015 in the British Virgin Islands for the purpose of engaging in initial business combination with one or more operating businesses. It is led by sponsors and management comprised of Iain Abrahams, Jonathan Mitchell, Mark Klein, and AAP Sponsor (PTC) Corp. AAPC has $7.48 million of capital in trust which includes the net proceeds raised in its initial public offering in May 2015.  AAPC’s ordinary shares are listed on the Nasdaq Capital Market (NASDAQ: AAPC).

Contacts

For further information please contact:

Where You Can Find More Information

This communication may be deemed to be solicitation material regarding the proposed Merger of Kalyx and AAPC, including the issuance of the common stock of KPI, the surviving public company.  In connection with the proposed Merger, AAPC expects to file a registration statement on Form S-4 (the “Form S-4”) and accompanying proxy materials with the Securities and Exchange Commission (“SEC”). INVESTORS AND SECURITY HOLDERS OF AAPC AND KALYX ARE URGED TO READ THESE MATERIALS, INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO, AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE MERGER THAT AAPC WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT AAPC, KALYX AND THE PROPOSED MERGER.  The preliminary proxy statement, the definitive proxy statement, and Form S-4 registration statement/prospectus, in each case as applicable, and other relevant materials in connection with the Merger (when they become available), and any other documents filed by AAPC with the SEC, may be obtained free of charge at the SEC’s website at www.sec.gov.  In addition, investors and security holders may obtain free copies of the documents filed with the SEC by contacting AAPC in writing at 590 Madison Ave, New York, NY, 10022.

Participants in the Merger

AAPC, Kalyx, and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the shareholders of AAPC in connection with the Merger.  Information regarding the officers and directors of AAPC is set forth in AAPC’s annual report on Form 10-K for the year ended December 31, 2016, which was filed with the SEC on March 15, 2017.  Additional information regarding the interests of such potential participants will also be included in the Form S-4 (and accompanying proxy materials) and other relevant documents filed with the SEC.

Cautionary Note Regarding Forward-Looking Statements

This communication may include “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipates”, “believes”, “continue”, “expects”, “estimates”, “intends”, “may”, “outlook”, “plans”, “potential”, “projects”, “predicts”, “should”, “will”, or, in each case, their negative or other variations or comparable terminology. Such forward-looking statements with respect to the timing of the proposed merger, as well as the expected performance, strategies, prospects and other aspects of the businesses of the parties to the Merger and the combined company after completion of the proposed merger, are based on current expectations that are subject to risks and uncertainties.

A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger (including the failure to consummate the PIPE); (2) the outcome of any legal proceedings that may be instituted against AAPC, Kalyx or others following announcement of the merger and the transactions contemplated therein; (3) the inability to complete the transactions contemplated by the Merger due to the failure to obtain approval of the shareholders of AAPC or Kalyx or other conditions to closing in the Merger; (4) the risk that we may be unable to secure a U.S. national exchange listing for KPI; (5) the risk that the proposed transaction disrupts current plans and operations as a result of the announcement and consummation of the Merger and the transactions described herein; (6) the ability to recognize the anticipated benefits of the Merger, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with tenants and retain its key employees; (7) costs related to the proposed Merger; (8) changes in applicable laws or regulations or their interpretation or application (including, notably, federal and state laws related to the use, cultivation and distribution of cannabis-based products); (9) the possibility that AAPC or Kalyx may be adversely affected by other economic, business, and/or competitive factors; (10) future exchange and interest rates; (11) delays in obtaining, adverse conditions contained in, or the inability to obtain necessary regulatory approvals or complete regulatory reviews required to complete the Merger; and (12) other risks and uncertainties indicated in the proxy statement to be filed by AAPC with the SEC, including those under “Risk Factors” therein, and other filings with the SEC by AAPC or Kalyx.  These factors are not intended to be an all-encompassing list of risks and uncertainties.

The forward-looking statements contained in this communication are based on our current expectations and beliefs concerning future developments and their potential effects on AAPC and Kalyx.  Future developments affecting AAPC and Kalyx may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and developments in the industry in which we operate may differ materially from those made in or suggested by the forward-looking statements contained in this release. In addition, even if our results or operations, financial condition and liquidity, and developments in the industry in which we operate are consistent with the forward-looking statements contained in this communication, those results or developments may not be indicative of results or developments in subsequent periods.

Disclaimer

This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

$INPX Q1 & Company Update, this Thursday, May 11

Inpixon (NASDAQ: INPX), a leading indoor positioning and data analytics company, today announced that it will issue First Quarter 2017 financial results for the period ended March 31, 2017, and provide an update on corporate developments at 4:05pm eastern time on Thursday, May 11, 2017.

Management will host a conference call on Thursday, May 11, 2017, at 4:30pm Eastern Time to review financial results and corporate highlights. Following management’s formal remarks, there will be a question and answer session.

To listen to the conference call, interested parties within the U.S. should call 1-844-824-3831. International callers should call +1-412-317-5141. All callers should ask for the Inpixon conference call. The conference call will also be available through a live webcast, which can be accessed at http://client.irwebkit.com/inpixon.

A replay of the call will be available approximately one hour after the end of the call through June 11, 2017. The replay can be accessed via Inpixon’s website or by dialing 1-877-344-7529 (U.S.) or +1-412-317-0088 (international). The replay conference playback code is 10107128.

About Inpixon

Inpixon (NASDAQ: INPX) is a leader in Indoor Positioning and Data Analytics. Inpixon sensors are designed to find all accessible cellular, Wi-Fi, and Bluetooth devices anonymously. Paired with a high performance, data analytics platform, this technology delivers visibility, security, and business intelligence on any commercial or government premises world-wide. Inpixon’s products, infrastructure solutions, and professional services group help customers take advantage of mobile, big data, analytics, and the Internet of Things (IoT) to uncover the untold stories of the indoors. For the latest insight on Indoor Positioning and Data Analytics, follow Inpixon on LinkedIn and @InpixonHQ on Twitter.

Safe Harbor Statement

All statements in this release that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Act, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of the control of Inpixon and its subsidiaries, which could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not limited to, the fluctuation of global economic conditions, the performance of management and employees, the Company’s ability to obtain financing, competition, general economic conditions and other factors that are detailed in the Company’s periodic and current reports available for review at www.sec.gov. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements.

$KTNNF Sully Project Exploration Update #SEDEX

KOOTENAY ZINC CORP.
Hugh Rogers
Director
info@kootenayzinc.com

Hammer Fiber Optics Holdings Corp. (OTCQB: HMMR)

Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX)

Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX), founded in 2015 and headquartered in Israel, is a technological innovator in automotive vision systems and driver assistance technology. Through its wholly owned subsidiary, Foresight Automotive Ltd., Foresight is engaged in the design, development and commercialization of stereo/quad-camera vision systems and V2X cellular-based solutions for the automotive industry based on 3D video analysis, advanced algorithms for image processing and sensor fusion. The company’s powerful and patented stereoscopic technology is derived from field-proven technology that has been deployed throughout the world for almost two decades.

Foresight’s innovative autonomous driving solutions are based on mature, proprietary stereoscopic image technology that uses two synchronized cameras to mimic human depth perception and produce a three-dimensional image. This 3D image can anticipate possible collisions with other vehicles, cyclists, pedestrians and other obstacles. The technology provides highly accurate real-time alerts about the vehicle’s surroundings while in motion. The systems are designed to improve driving safety by enabling highly accurate and reliable threat detection while ensuring the lowest rates of false alerts.

The company’s patents provide IP protection for its robust and proven proprietary stereoscopic technology, which was developed using the security technology of Foresight’s major shareholder, Magna B.S.P.

Foresight has developed three main products:

• QuadSight™. This breakthrough detection system sets the bar for autonomous vehicle vision. It features nearly 100 percent obstacle detection with almost zero false alerts and operates optimally under all weather and lighting conditions, including darkness, rain, fog, haze and glare. QuadSight™ is the first quad-camera multi-spectral vision solution of its kind, driven by advanced and proven image processing algorithms. The system consists of two sets of stereoscopic infra-red and visible-light cameras that enable highly accurate and reliable obstacle detection for seamless 24/7 vision.
• Eyes-On™. This solution uses advanced algorithms for accurate depth analysis and obstacle detection to provide a unique stereo vision Advanced Driver Assistance System (ADAS). It can detect all potential obstacles regardless of shape, form or material, including other vehicles, cyclists, pedestrians and animals. It has an accuracy and reliability of almost 100 percent and near zero false alerts.
• Eye-Net™. This is a cellular-based accident prevention solution that is designed to provide real-time pre-collision alerts to vehicles and pedestrians. This proprietary system is deployed on smartphones and cloud-based servers operating on existing cellular networks, and it eliminates the need for additional designated hardware. Eye-Net™ is designed to provide a complementary layer of protection to advanced driver assistance systems and extends this protection to road users who are not in direct line of sight. It is optimally designed for both urban environments and high-speed scenarios to provide protection for the most vulnerable road users. On March 28, 2018, Foresight announced that it had completed a successful feasibility study of its Eye-Net™ accident prevention solution involving 120 users of Android and iOS cell phones located across Israel.

In 2017, Foresight sought more opportunities within the international market. The Company signed pilot agreements with three leading car manufacturers in China and completed pilot projects meeting all pre-defined requirements and criteria. In addition, FRSX completed a pilot project with Uniti Sweden.

Studies by the Insurance Institute for Highway Safety continue to emphasize the dramatic reduction in accidents and injury-related crashes reported when vehicles are equipped with collision avoidance systems. A recent study by the Institute states that the rate of single-vehicle, sideswipe and head-on crashes was 11 percent lower in vehicles with the warning systems. More importantly, the study shows collision avoidance technology cut the rates of injury crashes of the same type by 21 percent.

Foresight Autonomous Holdings, Inc. also holds a 32 percent interest in RailVision, a company that develops advanced systems for railway safety and maintenance. RailVision has successfully completed 13 tests in Israel, Germany, Italy and Switzerland in addition to a real-time system test with a European railway operator. Over the course of 2017, RailVision successfully completed rounds of financing totaling $5.8 million and started the process of licensing the system according to European standards.

Haim Siboni is the founder of Foresight and has served as the company’s chief executive officer and director since 2015. Siboni, a passionate entrepreneur, has an extensive background in the marketing and business management sectors in the fields of electronics, video, TV, multimedia, computerized systems, line and wireless telecommunication, design and development of systems and devices, including electro-optic radar systems. He is the founder and CEO of Magna B.S.P., Foresight’s major shareholder and a leading innovator in the field of homeland security surveillance solutions.

Investment Considerations

• Developer of advanced accident prevention systems based on stereoscopic vision and V2X-technologies for the automotive industry
• Global collision avoidance sensors market expected to reach $50.38 billion by 2020
• Real-time demo systems for Eyes-On™ and Eye-Net™ operational and available for demonstration and data collection purposes
• QuadSight™ system is based on visible-light and infra-red cameras that detects objects under all weather and lighting conditions with near 100% detection and near zero false alerts

Earth Science Tech, Inc. (ETST)

Earth Science Tech, Inc. is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

• Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
• Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
• KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Investment Considerations

• Biotech company focused on production of cutting-edge industrial hemp, cannabis/cannabidiol (CBD) products
• R&D efforts include nutraceuticals, pharmaceuticals, bioceuticals, phytoceuticals and cosmeceuticals catering to health, wellness and alternative medicine markets
• International provisional patent application targets CBD’s powerful medicinal benefits
• Integration of CBD molecule with generic drug molecules opens new medical frontier
• Hemp-derived CBD product market expected to reach $3 billion by 2021
• Medical diagnostic device MSN-2 slated for clinical tests to validate detection of various STDs
• Global market for diagnostic testing of STDs expected to reach $108.5 billion by 2019

Emblem Corp. (TSX.V: EMC) (OTC: EMMBF)

Emblem Corp. is a publicly traded, fully integrated Canadian medical and adult recreational cannabis company led by a team of proven senior executives with experience in the pharmaceutical industry, the cannabis horticulture industry and health care.

Emblem is an “indoor” cannabis producer, growing in six controlled environment indoor grow rooms at its facility in Paris, Ontario. A seventh grow room will be added by spring 2018, which will bring Emblem’s total capacity to 2,400 kilograms per year at a cost-effective 1.5 grams per watt.

Emblem is licensed by Health Canada to produce cannabis oils using super critical CO2 extraction technology. The company is currently completing an expansion that will provide about 30,000 square feet to house a GMP extraction laboratory, pharmaceutical production and value-added product facility. In preparation for the Canadian adult recreational cannabis market expected to rollout by July 2018, Emblem is planning to build a 115,000 square foot facility with an indoor capacity of 15,000 kilograms at 1.5 grams per watt.

Emblem has adopted a three-part strategy to the Canadian cannabis industry:

• Targeting medical cannabis by focusing on the development and sale of cannabinoid-based pharmaceutical formulations; Emblem expects that more advanced cannabis formulations will displace dried flower and simple oils in the Canadian medical market.
• Targeting the adult recreational cannabis market by distinguishing its product offerings through growing high quality indoor dried flowers and developing unique value-added, extraction-based products.
• Targeting education and healthcare by providing medical cannabis patients with information and resources not generally available from the Canadian healthcare system.

The likely addition of cannabis-infused edibles and other concentrates to Canada’s legalization plans for marijuana are expected to produce significant revenue streams for the company. An amendment to Bill C-45, otherwise known as the Canadian Cannabis Act, would ensure these derivatives of cannabis will be available no later than 12 months after the country officially legalizes recreational cannabis in July 2018.

Emblem has invested several million dollars into its Pharma division to research marijuana drug candidates and potential new drugs derived from cannabis. Over time, the company expects this division to be the largest and most profitable as it focuses initially on bringing drugs to market that will address neuropathic pain, anxiety and sleep issues. By providing standardized, consistent doses of cannabinoid-based pills and oils, Emblem intends to lead the industry. Value-added products such as sustained release and accelerated release formulations will materially increase product demand. Emblem’s focus on regulating the growth environment by using a holistic, organic method means each cannabis strain is healthy and true to its mother plant, which in turn assures a naturally grown, robust medical cannabis product.

Emblem, which had 2,154 active patients as of August 2017, continues to enroll patients in its GrowWise Health program which is also seeing a marked expansion of its clinic network. Projected growth in this sector, along with the value-added benefits provided for patients and physicians, is expected to ensure ongoing patient registration. Emblem plans to open additional GrowWise Health clinic locations across Canada.

Covering the full cannabis spectrum, Emblem’s business is structured to reach new heights from growing to selling recreational and medical cannabis, to educating and assisting patients, to creating new forms of cannabinoid-based medications in standardized, high quality and convenient-to-use formulations.

Investment Considerations

• Licensed to cultivate and sell medical cannabis as well as cannabinoid oils
• Canada’s $8.7 billion base domestic retail cannabis market projected to skyrocket
• Recent agreements to purchase 80 acres enable the addition of three custom-built cultivation facilities, boosting production
• Anticipated production of 154,000 pounds of cannabis supports revenue projection of $516.2 million per year

Hiku Brands Co. Ltd. (DJACF)

Headquartered in British Columbia’s picturesque Okanagan Valley, DOJA™ Cannabis Company Ltd. (CSE: DOJA) (OTC: DJACF) is a premium cannabis lifestyle brand growing high-quality handcrafted cannabis flower. DOJA’s wholly owned subsidiary is a licensed producer of cannabis under the ACMPR that has requested its Pre-Sales License Inspection, the last step prior to receiving a license to sell cannabis under the ACMPR. DOJA’s Dominion Facility is a state-of-the-art ACMPR licensed production facility capable of producing approximately 660 kg year of dried cannabis flower. DOJA’s second facility, a 22,580 sq ft warehouse, “the FUTURE LAB”, is targeting its Phase 1 completion by Q2 2018 and once the facility is fully built-out utilizing an industry leading multi-tier system powered by LED lighting provided by Fluence BioEngineering, DOJA’s annual production capacity is expected to be in excess of 5,000 kgs. DOJA was founded by the proven entrepreneurial team that started SAXX Underwear®.

On December 21, 2017, DOJA and TS Brandco Holdings Inc. (“Tokyo Smoke”) announced that they have entered into a binding Letter of Intent (“LOI”) to merger the two companies and create a uniquely positioned cannabis company combining a best-in-class craft cannabis producer with an award-winning lifestyle brand and retail-focused cannabis company. It is anticipated that the combined company resulting from the merger will use the name “Hiku Brands Company Ltd.” (“Hiku”) to refer to the brand house containing premium cannabis brands DOJA, Tokyo Smoke, and Van der Pop.

DOJA recently closed on a $10 million strategic equity investment from Aphria Inc. (“Aphria”) (TSX:APH and US OTC: APHQF) to expand their product offering ahead of the recreational market.

Upon completion of the merger, Hiku will have a robust cash position of approximately $31 million, which it plans to invest in expanding its cannabis production capacity, growing its retail footprint, and adding select brands to its portfolio through highly strategic and complementary acquisitions.

About Tokyo Smoke
Founded in 2015 by Alan and Lorne Gertner, Tokyo Smoke is an award-winning cannabis lifestyle brand that brings sophistication and design to the fast-growing industry. With immersive experiences and design-first, non-dispensary retail spaces selling coffee, cannabis accessories and design products, the brand has six locations in Canada, with plans to expand nationwide. Recently named “Brand of the Year” at the Canadian Cannabis Awards, Tokyo Smoke has showcased excellence in brand storytelling, and has developed an international reputation as the go-to destination for engaging content offerings within the industry. With the acquisition of fellow designer cannabis brand Van der Pop, and by partnering with Aphria Inc. (TSX: APH and US OTC: APHQF) and WeedMD (TSXV: WMD), Tokyo Smoke continues to be the leading Canadian brand in the cannabis space.

About Hiku
Hiku is focused on handcrafted cannabis production, immersive retail experiences, and building a portfolio of iconic, engaging cannabis lifestyle brands. Hiku is differentiated as the only Canadian craft cannabis producer with a significant national retail footprint and a growing brand house including premium cannabis lifestyle brands DOJA, Tokyo Smoke, and Van der Pop.

Hiku’s wholly owned subsidiary, DOJA Cannabis Ltd., is a federally licensed producer pursuant to the ACMPR, owning two production facilities in the heart of British Columbia’s Okanagan Valley. The company operates a network of retail stores selling coffee, clothing and curated accessories, across British Columbia, Alberta and Ontario.

Investment Considerations

• Premium cannabis lifestyle brand founded by team that started SAXX Underwear®
• One of only 26 Health Canada licensed cannabis production facilities
• Canada’s recreational marijuana market estimated at up to $8.7 billion
• Initial cannabis harvests are complete; awaiting Health Canada pre-sales inspection

ChineseInvestors.com (CIIX)

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF)

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) is a lifestyle-oriented cannabis and cannabidiol (“CBD”) consumer products company with a portfolio of lifestyle brands customized to connect specific, like-minded customers. Each Green Growth Brand provides the best quality products within a retail experience that appeals to users in an environment that is emotionally branded and easy to navigate.

In the next five years, the cannabis industry will generate more than $28 billion of new revenue from an estimated 14 million new customers, according to Ackrell Capital’s 2018 Cannabis Investment Report. Meanwhile, Hemp Business Journal projects that the CBD market will increase 8x to $3 billion by 2021, up from $200 million in 2017. Green Growth Brand intends to dominate in these markets with a lineup up products grown, manufactured and presented with the highest quality standards in mind.

Products under the Green Growth Brand umbrella include:

• CAMP: A kiosk-type store where consumers can experience beautifully crafted lifestyle products that enhance one’s journey to self-discovery.
• Seventh Sense: A CBD-infused body care collection crafted from the finest botanicals and fragrances on earth. Created to maximize the properties and aromatics of each ingredient, Seventh Sense natural products are CBD-infused botanical therapy.
• Meri+Jayne: Fiercely authentic and wholly unapologetic, Meri+Jayne is a youthful, full-on celebration of what makes each person unique. Expect the unexpected when it comes to this mix of amazing products.
• Green Lily: A place for women to explore a new world of wellness. With advice on every product, from efficacy to usage, Green Lily guides guests through beautiful new ways to experience cannabis and CBD.
• The +Source: Located in Las Vegas and Henderson, Nevada, The+Source dispensaries operated by Green Growth Brands serve both medical patients and retail customers. Green Growth Brands also operates a grow and production facility in Post, Nevada, and recently entered into definitive agreements to acquire a Pahrump, Nevada, cultivation facility.
• XanthicBiopharms is the owner of valuable intellectual property that turns THC(Tetrahydrocannabinol) and CBD into a water-soluble substance. As a result of combining Green Growth Brands and Xanthic, this technology is being used to create incredible new products.

Business Strategy

Green Growth Brands has identified numeroushitches in the current cannabis retail space. The company intends to counter these challenges and provide a customer experience ripe with a friendly staff, in-stock assortments, efficient operations and more. The company’s retail partners provide distribution opportunities within 4,000 stores, as well as robust and established digital platforms to best reach the modern consumer.

Management

Green Growth Brands brings together a collection of expert retailers, scientists, botanists, developers, artists and business leaders for the benefit of building community. Led by an executive management team steeped in decades of experience with several of America’s most successful brands, including Victoria’s Secret, American Eagle Outfitters, Bath & Body Works, Limited Brands and Designer Shoe Warehouse, Green Growth Brands is uniquely positioned to create memorable brands, retail experiences, and quality products for the emerging cannabis industry.

Chief Executive Officer Peter Horvath heads strategy and execution across all company channels, and previously took shoe retailer DSW public on the NYSE at $1.5 billion. As a dynamic, creative brand leader, team builder, and specialty retail veteran with deep roots in finance, Horvath’s unique ability to understand the big picture while never missing the subtle details is a critical factor in Green Growth Brands’ success and brand popularity among customers.

Chief Marketing Officer Scott Razek is a brand strategist, storyteller and strategic marketer. Razek’s 25 years of experience in brand building, product development and customer experience focus are a key differentiator for the Green Growth Brands portfolio.

CAO Ed Kistner brings 33 years of multifaceted experience at leading retail businesses, notably in finance, merchandise planning, operations and stores. His well-rounded experiences in fast-changing environments position Kistner to be the architect of the operational execution at Green Growth Brands.

CSO Kellie Wurtzman brings significant retail leadership to Green Growth Brands with a proven track record of leading high-performance stores and teams across multiple retail sectors. Her unmatched experience in identifying and supporting developing business opportunities is ideal for evolving the cannabis industry and will be instrumental in expanding operations at Green Growth Brands.

Headquartered in Columbus, Ohio, Green Growth Brands is traded on the Canadian Securities Exchange and on the OTCQB, providing investors with increased access to data, transparency and liquidity.

Investment Considerations

• Over C$140 million total equity funds raised to date from top tier strategic investors
• Cannabis dispensaries in Nevada sold approximately $425 million of product, giving the state $70 million in taxes for the first full year of recreational adult-use sales
• Organic growth of Green Growth Brands in Nevada includes 8 retail cannabis dispensary licenses to operate in the state and two cultivation facilities, positioning the company to be one of the largest vertically integrated operators in Nevada
• At maturity, Nevada is seen as a consumer market representing $150 million to $250 million in revenue potential to Green Growth Brands as it builds to 10 or more dispensaries across multiple brand formats
• North American expansion strategy involves easy-to-navigate experience that involves a surprise element – localized, authentic consumer experiences
• Retail partners provide distribution opportunities in over 4,000 stores as well as through robust and established digital platforms
• Pending acquisition of Just Healthy LLC provides Green Growth Brands with a license for up to three medical cannabis dispensaries in Northampton, Massachusetts, along with a cultivation and processing site, in a potential $60 million market

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

GP Solutions (OTC: GWPD)

GP Solutions (OTC: GWPD) is developing scalable farming systems for soil-less indoor organic farming. The company’s GrowPods are automated micro-farms that use hydroponic technology and unique soil systems to cultivate the highest-quality specialty leaf crops. The system is designed and engineered for ease of use, allowing users to farm year-round in any location of the world, supporting the company’s mission to provide customers with the ability to cultivate their own organic “superfoods.”

GrowPod Design & Function

GrowPod is a modular, stackable and mobile vertical growing environment specifically engineered to maximize yield and automation. GrowPods are available as a vertical pod, stacker pod or custom-built pod.

The Stacker Pod is a certified organic soil system that offers growers multiple levels of planting in order to maximize space and produce options with different fruits and vegetables. The Vertical Pod utilizes a vertical hydroponic system. It is affordable, scalable, efficient, automated and sustainable. The output provides customers with fresh and clean produce year-round in any climate. The Custom Pod is built to suit the farmer’s specific crop and grow goals.

Each 320-square-foot GrowPod container will have an annual production capability of up to four times that of outdoor growing methods, dramatically increasing profitability to the grower. The controlled environment of the GrowPod ensures efficient power and water usage in growing a wide range of horticultural and agricultural products in all environments and climates.

Thanks to a combination of hydroponic and certified organic soil systems, crop yields are higher, faster, and more consistent that conventional means. Customers can enjoy an average of eight higher yield crop cycles anywhere in the world.

GrowPod Features:

• Modular, stackable and mobile
• Fully insulated, food-grade shipping container
• Engineered for automation
• Efficient LED lighting
• Hydroponic or soil-based platforms
• Proprietary air and water filtration
• Climate-controlled
• Remote monitoring

GP Solutions also offers many services to its customers, including:

• Shipment and installation service of its shipping container farms
• On-site training
• Provision of custom planting and harvesting schedule
• Provision of growing supplies, seeds, nutrients, packaging, branding and repair materials
• On-site visits, on-call and scheduled maintenance, and re-supply
• Remote monitoring and automated control of environmental nutrients, environmental growth factors (PH, temperature, light) and circulation
• Technical assistance
• Consulting and custom facility systems design

Competitive Advantage

GrowPods allow cultivation to take place year-round, which maximizes ROI. The systems are sealed from outside pathogens, contaminants, pesticides, and the result is clean and robust crop production.

GP Solutions also has a line of remarkable new proprietary soil mixtures and nutrient lines which contain no animal products. These products are vital, as many other soils and additives can contain harmful pathogens and contaminants that can cause crops to become tainted or fail rigorous testing.

Global Solution

GP Solutions has partnered with the world’s leading food nonprofit companies, including Feeding America, Seeds of Hope, Habitat for Humanity, Meals on Wheels America, L.A. Kitchen, and Farm Bread, to help insecure communities take control of their own food dependence using container farms.

Investment Considerations

• Developer of state-of-the-art custom farm containers for farmers, growers, restaurants, hotels, casinos, entrepreneurs, and investors throughout North America
• Featured in MarketWatch, Business Insider and Bloomberg, recognized for its innovation and contributions to end world hunger
• Modular, stackable and mobile GrowPod systems address the issues of providing a clean and safe food supply, reducing world hunger, maximizing crop yields, and offering a rapid and inexpensive pathway for entrepreneurs and businesses to enter multiple agricultural sectors
• GrowPods allow cultivation to take place year-round, which maximizes customers’ ROI

Millennial Lithium Corp. (TSX.V: ML) (FSE: A3N2) (OTC: MLNLF)

$DRAM Announces 1-for-4 Reverse Stock Split

Implemented to raise the per share trading price of Dataram’s common stock to more than $4.00 per share bid price in support of closing requirements for merger with U.S. Gold Corp.

PRINCETON, N.J., May 05, 2017 — Dataram Corporation (NASDAQ:DRAM) today announced the Company has approved a 1-for-4 reverse split.  The reverse stock split will be effective with The NASDAQ Capital Market (“NASDAQ”) at the open of business on Monday, May 8, 2017.   The par value and other terms of Company’s common stock were not affected by the reverse stock split.  Dataram’s common stock will begin trading on The NASDAQ Capital Market on a split-adjusted basis when the market opens on Monday, May 8, 2017.

The purpose of the reverse stock split is to raise the per share trading price of Dataram’s common stock to greater than $4.00 per share minimum bid price.  The reverse split is a condition to the consummation of the merger with U.S. Gold Corp. The common stock will continue to be traded on The NASDAQ Capital Market under the symbol “DRAM,” and the new CUSIP number for the Company’s common stock following the reverse stock split is 238108 500.

The Company’s shareholders voted at the special shareholders meeting held on March 30, 2017, to grant the Board of Directors the authority, in its sole direction, to effect a reverse stock split of the Company’s issued and outstanding common stock by a ratio of not less than 1-for-2 and not more than 1-for-10 at any time prior to March 30, 2018.  The Board of Directors has determined to fix the ratio for the reverse stock split at 1-for-4.

At the effective time of the reverse stock split, every four shares of Dataram’s issued and outstanding common stock will be converted automatically into one issued and outstanding share of common stock, without any change in par value. The reverse stock split will reduce the number of shares of Dataram’s common stock outstanding from approximately 4.8 million to approximately 1.2 million. In addition, pursuant to the reverse stock split, there will be a proportionate adjustment to (i)  the per share exercise price and the number of shares issuable upon the exercise or settlement of all outstanding options and warrants to purchase or acquire shares of Dataram’s common stock and (ii) the conversion of all outstanding shares of convertible preferred stock. In addition, the number of shares reserved for issuance pursuant to Dataram’s existing equity incentive compensation plans will be reduced proportionately. The number of authorized shares of the Company’s common and preferred stock was not affected by the reverse stock split.

No fractional shares will be issued as a result of the reverse stock split, and stockholders who otherwise would be entitled to a fractional share will receive, in lieu thereof, a cash payment based on the closing sale price of the Dataram’s common stock as reported today on The NASDAQ Capital Market. The Company’s transfer agent, Equity Stock Transfer LLC, is acting as exchange agent for the reverse stock split.  Equity Stock Transfer will provide instructions to stockholders of record regarding the process for exchanging shares.

About Dataram Corporation

Dataram is a manufacturer of memory products and provider of performance solutions that increase the performance and extend the useful life of servers, workstations, desktops and laptops sold by leading manufacturers such as Dell, Cisco, Fujitsu, HP, IBM, Lenovo and Oracle. Dataram’s memory products and solutions are sold worldwide to OEMs, distributors, value-added resellers and end users. Additionally, Dataram manufactures and markets a line of Intel Approved memory products for sale to manufacturers and assemblers of embedded and original equipment. 70 Fortune 100 companies are powered by Dataram. Founded in 1967, the Company is a US based manufacturer, with presence in the United States, Europe and Asia. For more information about Dataram, visit www.dataram.com.

Safe Harbor Statement
The information provided in this press release may include forward-looking statements relating to future events, such as the development of new products, pricing and availability of raw materials or the future financial performance of the Company, and the pending acquisition of U.S. Gold Corp, and any anticipated benefits of the merger, and the success of U.S. Gold with respect to any of its exploration activities. Actual results may differ from such projections and are subject to certain risks including, without limitation, risks arising from: changes in the price of memory chips, changes in the demand for memory systems, increased competition in the memory systems industry, order cancellations, delays in developing and commercializing new products, risks with respect to U.S. Gold faced by junior exploration companies generally engaged in pre-production activities, and other factors described in the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, filed with the Securities and Exchange Commission, which can be reviewed at www.sec.gov. The Company has based these forward-looking statements on its current expectations and assumptions about future events. While management considers these expectations and assumptions to be reasonable, they are inherently subject to significant business, economic, competitive, regulatory, and other risks, contingencies, and uncertainties, most of which are difficult to predict and many of which are beyond the Company’s control. The Company does not assume any obligations to update any of these forward-looking statements.

Source: Dataram Corporation

Dataram Contact:
Jeffrey Goldenbaum
Director, Marketing
609.799.0071
info@dataram.com

$MTFBW Appoints Dr. Craig Albanese as Non-Executive Director

NEW YORK, May 05, 2017 — Motif Bio plc (NASDAQ:MTFB) (AIM:MTFB.LN), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced the appointment of Dr. Craig T. Albanese to the Company’s Board as Non-Executive Director with immediate effect.

Dr. Albanese has 25 years of clinical and administrative experience focusing on children and women’s health, primarily in the Stanford Children’s Hospital, New-York Presbyterian Hospital, Morgan Stanley Children’s Hospital and the Sloane Hospital for Women. He has had a distinguished clinical career to date having published 161 peer review articles, contributed 57 book chapters, and risen to Professor of Surgery in Pediatrics, Obstetrics and Gynecology. He has combined his clinical career with success in hospital administrative positions where he has had a pivotal role in setting up networks of physicians, support, and educational services across a number of hospitals and medical institutions to provide integrated clinical and support services for increasing numbers of patients in a very cost-effective way.

Richard Morgan, Chairman of Motif Bio, commented, “I am delighted to welcome Craig to the Board of Motif Bio. We have seen great progress in the development of iclaprim, our lead antibiotic for serious Gram-positive infections, and with the publication of the successful completion of the first Phase III clinical trial, the Board is now increasingly focused on the commercialization of iclaprim in the US. Craig’s experience and knowledge of both the clinical reality and operational activities of large hospital groups will prove invaluable in refining our commercialization strategy for iclaprim. We look forward to his input to the team.”

The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:

–  Full name and age: Craig Thomas Albanese (aged 55)

Dr. Albanese has been granted options to acquire 100,000 ordinary shares of 1p each in the Company at a price of 33.75p. The options granted have a vesting period of 48 months, may be exercised up to the tenth anniversary of the grant and are not subject to performance criteria.

No further information in connection with his appointment is required to be disclosed under Schedule Two, paragraph (g) of the AIM Rules for Companies.

About Motif Bio plc www.motifbio.com

Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalized patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), infections often caused by MRSA (methicillin resistant Staphylococcus aureus). Having completed the REVIVE-1 trial, patients are currently being enrolled and dosed in a second global Phase 3 clinical trial (REVIVE-2) with an intravenous formulation of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-2 is expected in the second half of 2017.

Forward-Looking Statements

This press release contains forward-looking statements. Words such as “expect,” “believe,” “intend,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause Motif Bio’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Motif Bio believes that these factors include, but are not limited to, (i) the timing, progress and the results of clinical trials for Motif Bio’s product candidates, (ii) the timing, scope or likelihood of regulatory filings and approvals for Motif Bio’s product candidates, (iii) Motif Bio’s ability to successfully commercialize its product candidates, (iv) Motif Bio’s ability to effectively market any product candidates that receive regulatory approval, (v) Motif Bio’s commercialization, marketing and manufacturing capabilities and strategy, (vi) Motif Bio’s expectation regarding the safety and efficacy of its product candidates, (vii) the potential clinical utility and benefits of Motif Bio’s product candidates, (viii) Motif Bio’s ability to advance its product candidates through various stages of development, especially through pivotal safety and efficacy trials, and (ix) Motif Bio’s estimates regarding the potential market opportunity for its product candidates. More detailed information about the risks and uncertainties affecting Motif Bio plc is contained under the heading “Risk Factors” in Motif Bio plc’s registration statement on Form F-1 filed with the SEC, which is available on the SEC’s web site, www.sec.gov. Motif Bio plc undertakes no obligation to update or revise any forward-looking statements.

For further information please contact:

Motif Bio plc Contact:
Graham Lumsden
Chief Executive Officer
ir@motifbio.com

Investor Contact:
Patricia L. Bank
Westwicke Partners
415-513-1284
patti.bank@westwicke.com

$REGI Welcomes Trade Commission Decision on Biodiesel Imports

AMES, Iowa, May 05, 2017  — Renewable Energy Group (NASDAQ:REGI) welcomes today’s unanimous decision by the U.S. International Trade Commission (ITC) to proceed with its investigation into whether biodiesel imports from Argentina and Indonesia may harm American producers.

In a 5-0 vote, the Commission agreed to proceed with a trade petition brought by a coalition of U.S. biodiesel producers.

REG Chief Financial Officer Chad Stone, who testified before the ITC last month as part of the National Biodiesel Board Fair Trade Coalition, issued the following statement:

“Today’s unanimous vote by the ITC is a key step in stopping unfair biodiesel trade practices that significantly harm U.S. biodiesel producers and American jobs. While we welcome healthy and fair competition, we cannot ignore unfair trade practices that threaten the domestic biodiesel industry that supports tens of thousands of American jobs, promotes energy security and improves our environment.”

About Renewable Energy Group

Renewable Energy Group, Inc. (NASDAQ:REGI) is a leading provider of cleaner, lower carbon intensity products and services. We are an international producer of biomass-based diesel, a developer of renewable chemicals and are North America’s largest producer of advanced biofuel. REG utilizes an integrated procurement, distribution, and logistics network to convert natural fats, oils, greases, and sugars into lower carbon intensity products. With 14 active biorefineries, a feedstock processing facility, research and development capabilities and a diverse and growing intellectual property portfolio, REG is committed to being a long-term leader in bio-based fuel and chemicals.

Note on Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to future actions involving an ongoing investigation by the ITC. These forward-looking statements are based on current expectations and assumptions, are subject to change, and actual results may differ materially. Factors that could cause actual results to differ materially include the inherent uncertainty as to how the ITC investigation will proceed and the results and timing of the investigation.  All forward-looking statements are made as of the date of this press release and REG does not undertake to update any forward-looking statements based on new developments or changes in our expectations.

Media Contact
Anthony Hulen
Executive Director, Corporate Affairs
+ (703) 822-1972
anthony.hulen@regi.com

$IMMU Delivers Business Updates, Announces Private Placement Offering

Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or “the Company”) today delivered several business and leadership updates and outlined a new strategic plan to drive long-term value for stockholders. These updates include the termination of the previously announced Exclusive Global Licensing Agreement with Seattle Genetics (NASDAQ:SGEN), returning full rights of Sacituzumab Govitecan (“IMMU-132”), the Company’s breakthrough therapy candidate to treat metastatic triple-negative breast cancer (mTNBC), to Immunomedics. Immunomedics also announced that it has raised $125 million in gross proceeds in a private placement of its Series A-1 Convertible Preferred Stock with institutional investors, and has taken a series of steps to drive positive organizational and operational changes.

Behzad Aghazadeh, Chairman of the Board of Immunomedics, stated: “We are pleased to announce these significant developments and to provide this new level of clarity regarding the progress that has been made at Immunomedics and the future direction of the Company. After conducting a full multi-faceted review of the organizational, operational, and clinical and regulatory capabilities, we are confident that Immunomedics can fully execute on a strategic plan over the next several years to become a recognized leader in the field of antibody-drug conjugates. We now have the financial ability to fully focus on taking the steps to ensure the Company has the right leadership, organizational structure and resources necessary to bring IMMU-132 to market and achieve our long-term objectives. The enthusiastic reception from institutional investors to invest in Immunomedics and IMMU-132 reflects the value the Company is poised to deliver to patients, employees and stockholders.”

Mutual Termination of Exclusive Global Licensing Agreement with Seattle Genetics

Under the termination agreement, the Company will retain all rights to IMMU-132. Seattle Genetics will maintain its existing equity investment in Immunomedics granted as part of the licensing agreement. Further, the expiration date for the warrants has been shortened to the later of December 31, 2017 and the date that is six (6) months following the date on which a sufficient number of shares of the Company’s Common Stock are authorized and reserved for issuance to permit the full exercise of such warrants. In addition, the termination agreement provides that no payments or expense reimbursements shall be made by either party and each party has provided full releases to the other party. Aspects of the mutually agreed upon termination of the licensing agreement between Immunomedics and Seattle Genetics are subject to court approval.

Business Updates

The newly elected Immunomedics Board of Directors has conducted a multifaceted review of the Company with initial emphasis on IMMU-132 in mTNBC, which had received Breakthrough Therapy Designation for this indication from the U.S. Food and Drug Administration in February 2016. The work streams have focused on the organizational, operational, and clinical and regulatory capabilities, with each being led by highly credentialed independent consultants with specific relevant expertise. These efforts have resulted in an updated timeline for the execution of delivering IMMU-132 to market, with the Company now targeting the submission of a BLA for IMMU-132 for approval in mTNBC between late fourth quarter 2017 and first quarter 2018, subject to FDA input on the acceptance of the CMC filing plan. Importantly, this review confirmed that the data generated in the ongoing 100-patient phase 2 study of IMMU-132 in 3^rd line TNBC, which was fully enrolled in December 2016, can provide the basis for accelerated approval, subject to review by the FDA.

This review has furthermore led to detailed filing and manufacturing plans. Alongside the immediate focus on preparations for a BLA filing, the Company will proceed with the final selection of a CRO to launch the confirmatory phase 3 study with the expectation of first patient enrolled in late Q3 2017, as well as executing on a manufacturing plan to build commercial inventory in preparation for a potential launch in the U.S. in 2018.

Over the course of the upcoming months, the scope of the ongoing strategic review will expand with the goal of executing on the following key initiatives:

• Develop plans for IMMU-132 beyond mTNBC
• Explore strategic opportunities for IMMU-132 with regional partners
• Execute an orderly management succession plan

The Board will provide additional updates to stockholders on these initiatives periodically.

Announcement of Private Placement

The Company has designated and agreed to sell 1,000,000 shares of Series A-1 Preferred Stock which are initially convertible into an aggregate of 23,105,360 shares of common stock, upon the approval by the Immunomedics stockholders of a charter amendment to increase the number of authorized shares of common stock to enable full conversion of the Series A-1 Preferred Stock. The price per share of the Series A-1 Preferred Stock is $125.00, which equates to an underlying price per share of common stock $5.41 (the closing price of Immunomedics common stock at the close of trading on May 4, 2017). The aggregate number of shares of Common Stock issuable upon conversion of the Preferred Stock is 23,105,360. Immunomedics expects to use the net proceeds from the $125 million private placement to support the development of IMMU-132, including the goal of filing a BLA for Accelerated Approval from the FDA. The capital will also fund general corporate and operational enhancements. With this new capital and the Company’s current cash on hand, Immunomedics expects to have sufficient operating funds through the third quarter of 2018. As of March 31, 2017, cash and cash equivalents were $46 million. The charter amendment needed to effect the conversion to common stock is subject to a stockholder vote, for which the Company expects to file a proxy statement with the Securities Exchange Commission in the near future. The authorization of additional shares is subject to a shareholder vote, which the Company will seek in the near future.

The securities offered by the Company in the private placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities laws and may not be offered or sold in the United States absent such registration or an applicable exemption from registration requirements. This press release is being issued for informational purposes pursuant to Rule 135c of the Securities Act and shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Leadership Transition Update

Immunomedics also announced today that effective upon the execution of the settlement agreement memorializing the terms of the binding settlement term sheet, Cynthia L. Sullivan will be stepping down from all director and officer positions with the Company, including her role as president and chief executive officer. Michael R. Garone, the current chief financial officer of Immunomedics, will then assume the role of interim CEO.

In addition, Dr. David M. Goldenberg, founder of the Company, is stepping down from all officer positions with the Company, including as chief scientific officer and chief patent officer, effective upon the execution of the settlement agreement. Dr. Goldenberg will continue to serve as a director on Immunomedics’ Board.

“It has been a pleasure to lead Immunomedics to this pivotal stage in its growth,” commented Ms. Sullivan. “I am confident that the board and leadership team will continue the work of bringing IMMU-132 to patients as soon as possible.”

“On behalf of the entire Board, we would like to thank Cynthia and David for their contributions to the Company and the incredible scientific potential they have positioned Immunomedics to be able to realize,” added Dr. Aghazadeh. “We look forward to continuing to work with David in his capacity as a director moving forward.”

With these transition steps in place, the Board plans on deciding on a permanent CEO and filling out additional leadership positions within the Company.

Litigation Update

In addition to the Company’s resolution of its claims against Seattle Genetics, the Company entered into a binding term sheet with Goldenberg, Sullivan, Markison and venBio, which will be memorialized in a settlement agreement (the “Settlement Agreement”) that will be subject to court approval. If approved, both the Federal Action¹ as well as the 225 Action² will be dismissed. Yesterday, in accordance with the term sheet, the Court of Chancery entered an order lifting the provisions of the Status Quo Order, and confirming that the Status Quo Board is the lawful Board of the Company (provided that if the 225 Action is not dismissed, the Parties shall be restored to their positions in the 225 Action as of immediately prior to the execution of the term sheet). Upon the execution of the Settlement Agreement, the Parties will immediately submit a stipulation and proposed order dismissing the 225 Action with prejudice. The Settlement Agreement will include a mutual release of all claims that were or could have been asserted in the 225 Action.

The Federal Action challenging the annual meeting will be dismissed. Upon execution of the Settlement Agreements, the Parties will immediately submit a stipulation and order dismissing the claims in the Federal Action with prejudice. The Settlement Agreement will include a mutual release of all claims that were or could have been asserted in the Federal Action.

Regarding the venBio Action³, individual defendants Goldenberg, Sullivan and Markison will be released from all claims made by venBio. Once the Parties execute the Settlement Agreement, it will be submitted to the Court of Chancery for approval. As to all other claims, including those asserted against the remaining individual defendants (former directors Robert Forrester, Jason Aryeh, Geoff Cox and Bob Oliver) and Greenhill, the parties will stipulate to stay the action and venBio and the Company will submit the remaining claims to non-binding mediation.

“Today’s announcements collectively represent an important milestone in the next phase of Immunomedics, and while there is significant work ahead, the Board looks forward to continuing to drive value for all stakeholders. The Company has a strong pipeline that we look forward to evaluating and intend to leverage to maximize the value for stockholders. We will be providing additional updates, including with our quarterly earnings release, as appropriate in the coming weeks and months,” concluded Dr. Aghazadeh.

Advisors

Cowen and Company, LLC acted as sole placement agent to Immunomedics in connection with the offering and DLA Piper LLP (US) is serving as legal advisor to the Company on the transaction.

About Immunomedics

Immunomedics (the “Company”) is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Immunomedics’ advanced proprietary technologies allow the Company to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. Using these technologies, Immunomedics has built a pipeline of eight clinical-stage product candidates. Immunomedics’ portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a specific payload of a chemotherapeutic directly to the tumor while reducing overall toxicities that are usually found with conventional administration of these chemotherapeutic agents. Immunomedics’ most advanced ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase 2 trials for a number of solid tumors and metastatic colorectal cancer, respectively. IMMU-132 has received Breakthrough Therapy Designation from the FDA for the treatment of patients with triple-negative breast cancer who have failed at least two prior therapies for metastatic disease. Immunomedics has a research collaboration with Bayer to study epratuzumab as a thorium-227-labeled antibody. Immunomedics has other ongoing collaborations in oncology with independent cancer study groups. The IntreALL Inter-European study group is conducting a large, randomized Phase 3 trial combining epratuzumab with chemotherapy in children with relapsed acute lymphoblastic leukemia at clinical sites in Australia, Europe, and Israel. Immunomedics also has a number of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various stages of clinical and preclinical development. These include combination therapies involving its antibody-drug conjugates, bispecific antibodies targeting cancers and infectious diseases as T-cell redirecting immunotherapies, as well as bispecific antibodies for next-generation cancer and autoimmune disease therapies, created using its patented DOCK-AND-LOCK® protein conjugation technology. The Company believes that its portfolio of intellectual property, which includes approximately 310 active patents in the United States and more than 400 foreign patents, protects its product candidates and technologies. For additional information on the Company, please visit its website at www.immunomedics.com. The information on its website does not, however, form a part of this press release.

Cautionary note regarding forward-looking statements

This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials (including the funding therefor, anticipated patient enrollment, trial outcomes, timing or associated costs), regulatory applications and related timelines, out-licensing arrangements, forecasts of future operating results, potential collaborations, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, the Company’s dependence on business collaborations or availability of required financing from capital markets, or other sources on acceptable terms, if at all, in order to further develop our products and finance our operations, new product development (including clinical trials outcome and regulatory requirements/actions), the risk that we or any of our collaborators may be unable to secure regulatory approval of and market our drug candidates, risks associated with the outcome of pending litigation and competitive risks to marketed products, and the Company’s ability to repay its outstanding indebtedness, if and when required, as well as the risks discussed in the Company’s filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

¹ “Federal Action” refers to the action captioned Immunomedics, Inc. v. venBio Select Advisor LLC, et al., C.A. No. 17-176-LPS.

² “225 Action” refers to the action captioned David M. Goldenberg et al. v. Behzad Aghazadeh et al., C.A. No. 2017-0163-JTL (Del. Ch.)

³ “venBio Action” refers to the action captioned venBio Select Advisor LLC v. David M. Goldenberg et.al, C.A. No. 2017-0108-JTL (Del. Ch.).

$RNN Effects 1-for-10 Reverse Stock Split

ROCKVILLE, Md., May 05, 2017 — Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) (“Rexahn” or the “Company”), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that the Company’s previously announced 1-for-10 reverse split (the “Reverse Stock Split”) of its common stock (the “Common Stock”) became effective today prior to the opening of trading on the NYSE MKT, and that the Common Stock will begin trading on a split-adjusted basis at the opening of trading today.

As a result of the reverse stock split, each 10 shares of issued Common Stock were converted into one share of Common Stock. Shareholders will receive cash in lieu of any fraction of a share that they would otherwise be entitled to receive as a result of the reverse stock split. The reverse stock split reduced the number of shares of outstanding Common Stock from approximately 254 million, to approximately 25.4 million and the number of shares of Common Stock the Company is authorized to issue was reduced from 500 million to 50 million.

Olde Monmouth Stock Transfer Co., Inc., the Company’s transfer agent, is acting as the exchange agent in connection with the reverse stock split.  Shareholders holding Common Stock in certificated form will receive instructions from the transfer agent on how to surrender the certificates representing the pre-split shares in exchange for the new book-entry shares in electronic form.  Shareholders who hold their shares electronically or in street name are not required to take any action to effect the exchange of their shares.

About Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals Inc. (NYSE MKT:RNN) is a clinical stage biopharmaceutical company dedicated to developing novel, best-in-class therapeutics for the treatment of cancer. The Company’s mission is to improve the lives of cancer patients by developing next generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment. Rexahn’s product candidates work by targeting and neutralizing specific proteins believed to be involved in the complex biological cascade that leads to cancer cell growth. Preclinical studies show that certain of Rexahn’s product candidates may be effective against multiple types of cancer, drug resistant cancer and difficult-to-treat cancers, and others may augment the effectiveness of current FDA-approved cancer treatments. The Company has a broad oncology pipeline that includes three anti-cancer compounds currently in clinical development: Supinoxin™, RX-3117, and Archexin^®, and a novel nanopolymer-based drug delivery platform technology that may increase the bio-availability of FDA-approved chemotherapies. For more information about the Company and its oncology programs, please visit www.rexahn.com.

Safe Harbor

To the extent any statements made in this press release deal with information that is not historical, these are forward looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the timing and effectiveness of the reverse stock split and the authorized share reduction, statements about the objectives of the reverse stock split, and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Rexahn’s actual results to be materially different than those expressed in or implied by Rexahn’s forward-looking statements. For Rexahn, particular uncertainties and risks include, among others, understandings and beliefs regarding the role of certain biological mechanisms and processes in cancer; drug candidates being in early stages of development, including in pre-clinical development; the ability to initially develop drug candidates for orphan indications to reduce the time-to-market and take advantage of certain incentives provided by the U.S. Food and Drug Administration; and the ability to transition from our initial focus on developing drug candidates for orphan indications to candidates for more highly prevalent indications. There can be no assurance that the reverse stock split will result in a sustained increased stock price or increased interest and trading in Rexahn’s common stock. More detailed information on the factors that could affect Rexahn’s actual results are described in Rexahn’s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. Rexahn undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact:
LifeSci Advisors, LLC
Matthew P. Duffy
(212)-915-0685
matthew@lifesciadvisors.com

$CIIX Appoints Summer Yun as CEO of CBD Biotechnology Subsidiary

SAN GABRIEL, California, May 2, 2017 –

ChineseInvestors.com, Inc. (OTCQB: CIIX) (“CIIX” or the “Company”), the premier financial information website for Chinese-speaking investors, today announces that it has appointed Summer (XiangYang) Yun as Chief Executive Officer (CEO) of its wholly-owned foreign entity, CBD Biotechnology Co., Ltd. (“XiBiDi Biotech”). XiBiDi Biotech’s primary focus is online, retail and direct sales of hemp-based health products in China. Yun’s initial focus will be the launch of ‘CBD Magic Hemp Series’ cosmetics line. He will also spearhead the Company’s plan to import natural dietary supplements created using advanced extracting and purifying technologies into China. Yun is a marketing and branding executive with over 25 years of experience. Yun will report directly to CIIX’s CEO Warren Wang.

“I am honored to be named as CEO of CBD Biotech,” says Yun. “For over 5,000 years, hemp has been cultivated and used in over 25,000 products worldwide. CIIX has a unique opportunity to become one of the first companies to offer CBD-based skin care products in China online and through established retail and direct selling channels. Through the introduction of Magic CBD Series cosmetics to China, I hope to educate consumers regarding hemp’s many benefits.”

The CBD Magic Hemp Series line will include cleansers, moisturizing lotions and anti-aging products created using supercritical CO₂ extraction technology. CBD Biotech also plans to launch a series of oral spray vitamins and supplements that can be used for relaxation, pain relief and sleep, among others things. Yun will oversee marketing and sales of these products in China, and utilizing his branding and marketing expertise, he will work to grow the CBD Biotech brand.

“I believe Yun is the perfect candidate to oversee CBD Biotech’s operations. I am confident in his ability to introduce this revolutionary CBD-based skin care line to China and create and generate substantial revenue for CIIX,” says Wang.

Yun served as a marketing executive for the cosmetics branch company of TianJing Department Store to introduce both Procter & Gamble and Ponds to the Chinese market. As a brand agent, Yun experienced how Procter & Gamble cooperated with GuangZhou Soap Factory to enter the Chinese market, where he introduced the Head & Shoulders and Olay brands to the Chinese market. In 1996, Yun founded Sino-US Trade Development Co., Ltd. in TianJing Development Zone, and at the same time introduced the French L’anfu Cosmetics brand and Shanghai L’anfu Cosmetics brand to the Chinese market. Over the past 28 years, Yun has served as Chinese brand agent to many major skin and health care brands.

About ChineseInvestors.com (OTCQB: CIIX)

Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail and online sales of hemp-based products and other health related products

For more information visit ChineseInvestors.com

Subscribe and watch our video commentaries: https://www.youtube.com/user/Chinesefncom

Follow us on Twitter for real-time Company updates: https://twitter.com/ChineseFNEnglsh

Like us on Facebook to receive live feeds: https://www.facebook.com/Chinesefncom

Add us on WeChat: Chinesefn or download iPhone iOS App: Chinesefn.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Contact:
ChineseInvestors.com, Inc.
227 W. Valley Blvd, #208 A
San Gabriel, CA 91776

Investor Relations:
Alan Klitenic
+1-214-636-2548

Corporate Communications:
NetworkNewsWire (NNW)
New York, New York
http://www.NetworkNewsWire.com
+1-212-418-1217 Office
Editor@NetworkNewsWire.com

$OLED Directors Announce Quarterly Cash Dividend of $0.03 per Share

Universal Display Corporation (Nasdaq: OLED), enabling energy-efficient displays and lighting with its UniversalPHOLED^® technology and materials, today announced that its Board of Directors approved a second quarter cash dividend of $0.03 per share on the company’s common stock. The dividend is payable on June 30, 2017 to shareholders of record as of the close of business on June 15, 2017. Future dividends will be subject to Board approval.

About Universal Display Corporation

Universal Display Corporation (Nasdaq: OLED) is a leader in developing and delivering state-of-the-art, organic light emitting diode (OLED) technologies, materials and services to the display and lighting industries. Founded in 1994, the Company currently owns or has exclusive, co-exclusive or sole license rights with respect to more than 4,200 issued and pending patents worldwide. Universal Display licenses its proprietary technologies, including its breakthrough high-efficiency UniversalPHOLED® phosphorescent OLED technology that can enable the development of low power and eco-friendly displays and solid-state lighting. The Company also develops and offers high-quality, state-of-the-art UniversalPHOLED materials that are recognized as key ingredients in the fabrication of OLEDs with peak performance. In addition, Universal Display delivers innovative and customized solutions to its clients and partners through technology transfer, collaborative technology development and on-site training.

Headquartered in Ewing, New Jersey, with international offices in China, Hong Kong, Ireland, Japan, South Korea, and Taiwan, and wholly-owned subsidiary Adesis, Inc. based in New Castle, Delaware, Universal Display works and partners with a network of world-class organizations, including Princeton University, the University of Southern California, the University of Michigan, and PPG Industries, Inc. The Company has also established relationships with companies such as AU Optronics Corporation, BOE Technology, DuPont Displays, Inc., Innolux Corporation, Kaneka Corporation, Konica Minolta Technology Center, Inc., LG Display Co., Ltd., Lumiotec, Inc., OLEDWorks LLC, OSRAM, Pioneer Corporation, Samsung Display Co., Ltd., Sumitomo Chemical Company, Ltd., Tianma Micro-electronics Co., and Tohoku Pioneer Corporation. To learn more about Universal Display Corporation, please visit http://www.oled.com.

Universal Display Corporation and the Universal Display Corporation logo are trademarks or registered trademarks of Universal Display Corporation. All other company, brand or product names may be trademarks or registered trademarks.

All statements in this document that are not historical, such as those relating to Universal Display Corporation’s technologies and potential applications of those technologies, the Company’s expected results and future declaration of dividends, as well as the growth of the OLED market and the Company’s opportunities in that market, are forward-looking financial statements within the meaning of the Private Securities Litigation Reform Act of 1995. You are cautioned not to place undue reliance on any forward-looking statements in this document, as they reflect Universal Display Corporation’s current views with respect to future events and are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated. These risks and uncertainties are discussed in greater detail in Universal Display Corporation’s periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission, including, in particular, the section entitled “Risk Factors” in Universal Display Corporation’s annual report on Form 10-K for the year ended December 31, 2016. Universal Display Corporation disclaims any obligation to update any forward-looking statement contained in this document.

Follow Universal Display Corporation

Twitter
Facebook
YouTube

(OLED-C)

Universal Display Corporation
Darice Liu, 609-671-0980 x570
investor@oled.com
media@oled.com

$SQBG and QVC Announce Multi-Year Collaboration for Martha Stewart Brand

America’s Most Trusted Lifestyle Expert to Appear on QVC

NEW YORK, May 04, 2017 — Sequential Brands Group, Inc. (Nasdaq:SQBG) (“Sequential” or the “Company”) and QVC, Inc. announced today a multi-year agreement for the Martha Stewart brand. Under the new agreement, QVC will launch several categories for the brand including skincare, fashion apparel, and food and beverage.

“Our brand has always been devoted to teaching and inspiring people to live more beautiful, more functional and more meaningful lives and our products provide solutions to do just that,” said Martha Stewart. “I am thrilled to partner with QVC, which offers unique opportunities to engage directly with an even broader audience, bringing to life several new categories for the Martha brand including beauty and fashion.”

The new collaboration, which is expected to launch in the second half of this year, will feature frequent appearances on QVC by Martha Stewart and a team of Martha’s favorite experts as they showcase new and exciting products and share tips on how to incorporate them into everyday living.

“QVC at its core is about the joy of discovery and the power of relationships, and few do a better job of connecting with fans and inspiring them to embrace new ideas than Martha Stewart,” said Mike George, QVC President and CEO.  “QVC combines the best of retail, media and social to create the most engaging shopping experience, and to collaborate with a brand such as Martha’s further emphasizes our commitment to excellence and innovation. By leveraging the power of this relationship, QVC, which is among the nation’s top mobile and eCommerce retailers, brings to our customers Martha’s passion and expertise in a special and exciting new way.”

Sequential Brands Group CEO, Karen Murray, added “QVC’s proven differentiated retail experience plays perfectly with the strength of the Martha Stewart brand.  We are excited by this opportunity as it provides the brand with a new channel of distribution and further expansion into untapped categories where we see strong sales potential.”

Martha Stewart is an Emmy Award-winning television show host, entrepreneur, bestselling author of 88 books, and America’s most trusted lifestyle expert and teacher. Millions of people rely on Martha Stewart as a source of useful “how-to” information for all aspects of everyday living – cooking, entertaining, gardening, home renovating, collecting, organizing, crafting, holidays, healthy living and pets. Currently, the Martha Stewart brand reaches approximately 100 million consumers across all media and merchandising platforms each month.

About Sequential Brands Group, Inc.
Sequential Brands Group, Inc. (Nasdaq:SQBG) owns, promotes, markets, and licenses a portfolio of consumer brands in the fashion, active, and home categories, which includes the Martha Stewart media and merchandising properties. Sequential seeks to ensure that its brands continue to thrive and grow by employing strong brand management, design and marketing teams. Sequential has licensed and intends to license its brands in a variety of consumer categories to retailers, wholesalers and distributors in the United States and around the world. For more information, please visit Sequential’s website at: www.sequentialbrandsgroup.com. To inquire about licensing opportunities, please email: newbusiness@sbg-ny.com.

About QVC
QVC combines the best of retail, media and social to create the most engaging shopping experience, one that exceeds the expectations of everyone we touch by delivering the joy of discovery through the power of relationships.  Every day, in nine countries and counting, QVC engages millions of shoppers in a journey of discovery through an ever-changing collection of familiar brands and fresh new products, from home and fashion to beauty, electronics and jewelry. Along the way, we connect with shoppers via live dialog, engaging stories, interesting personalities and award-winning customer service. Based in West Chester, Pa. and founded in 1986, QVC has more than 17,000 employees and has retail operations in the U.S., Japan, Germany, United Kingdom, Italy, France, and through a joint venture in China. Worldwide, QVC engages shoppers via 15 TV channels reaching more than 360 million homes, seven websites, and 195 social pages. Visit corporate.qvc.com to learn more.

QVC is a wholly owned subsidiary of Liberty Interactive Corporation and is attributed to the QVC Group tracking stock (NASDAQ: QVCA, QVCB). Liberty’s QVC Group also includes zulily, a digital retailer obsessed with bringing customers special finds every day at incredible prices. zulily has been a wholly-owned subsidiary of Liberty Interactive Corporation since October 2015. zulily features an ever-changing, always delightful collection of clothing, home décor, toys, gifts and more––for the whole family. Unique products from up-and-coming brands are featured alongside favorites from top brands, giving customers something new to discover each morning. Launched in 2010, zulily is headquartered in Seattle. Among mass merchants, the combined QVC Group (including QVC and zulily) is the #3 mobile retailer in the U.S., the #8 mobile retailer globally, and the #4 ecommerce player in North America, according to Internet Retailer. QVC, Q, and the Q Ribbon Logo are registered service marks of ER Marks, Inc. For more information on Liberty Interactive Corporation, visit www.libertyinteractive.com.

The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.

Media Contacts:

Sequential Brands Group
Jaime Cassavechia, 212-518-4771 x108
jcassavechia@sbg-ny.com

QVC
Jane Crawford, 484-701-1506
Jane.Crawford@qvc.com

Investor Relations:

Sequential Brands Group
Katherine Nash, 512-757-2566
knash@sbg-ny.com 

Liberty Interactive Corporation 
Courtnee Chun, 720-875-5420
Courtnee@libertymedia.com

$EMKR Selected as 2017 Raytheon Supplier Excellence Program Premier Award Winner

ALHAMBRA, Calif., May 04, 2017 — EMCORE Corporation (NASDAQ:EMKR), a leading provider of advanced Mixed-Signal Optics products that provide the foundation for today’s high-speed communication network infrastructures and leading-edge defense systems, announced today that Raytheon has recognized EMCORE with a Premier Supplier Excellence Award for their outstanding achievement. Premier awards are awarded to Suppliers whom have demonstrated premier achievement for Raytheon in Business Management, Technical, Partnership, or Affordability. Only the highest achieving Suppliers are awarded this honor. EMCORE Corporation has been selected to receive a Premier Award for its overall Commitment to Affordability.

As part of the Raytheon Supplier Excellence Program, suppliers are awarded for their outstanding performance, contributions, and support for Raytheon’s programs. EMCORE has worked closely with Raytheon in development of advanced navigation systems based on its Fiber Optic Gyroscope (FOG) and Inertial Measurement Unit (IMU) technology, which deliver industry-leading performance at lower cost, with lower Size, Weight and Power (SWaP) requirements than competing systems.

“On behalf of Dr. KK Wong, Director of R&D; David Faulkner, our new VP and GM for aerospace and defense products; and the entire FOG team at EMCORE, I would like to thank Raytheon for selecting EMCORE as a Supplier Excellence Program Premier Award Winner,” said Jeffrey Rittichier, President and CEO of EMCORE. “This a tremendous honor for EMCORE. We have a long and proud history of research and development in advanced optics for specialized aerospace systems, and we have been honored to work so closely with Raytheon to develop our FOG technology for their programs.”

“After many years of collaboration with Raytheon in support of their programs, we are extremely honored to be selected by Raytheon’s Supplier Excellence Program,” said Dr. KK Wong, Senior Director of Fiber Optic Gyro Products for EMCORE. “Our team has worked very hard to achieve the performance and cost standards required, and I thank them so much for their dedication, skill and excellence,” added Dr. Wong.

“Since joining EMCORE I’ve observed first-hand the commitment of our highly-skilled FOG technical team under the direction of Dr. KK Wong,” said David Faulkner, EMCORE’s Vice President and General Manager, Aerospace & Defense. “I am very pleased for KK and his team who are so deserving of this award.”

EMCORE’s will showcase its complete line of Fiber Optic Gyro and Inertial Navigation products at the 2017 Space Tech Expo, May 23-25 at the Pasadena Convention Center, Pasadena, CA, booth #8008. EMCORE will also be at the Joint Navigation Conference (JNC) hosted by the Institute of Navigation (ION), June 6-7 at Dayton Convention Center in Dayton, Ohio, booth #310A.

About EMCORE
EMCORE Corporation is a leading provider of advanced Mixed-Signal Optics products that provide the foundation for today’s high-speed communication network infrastructures and leading-edge defense systems. Our optical chips, components, subsystems and systems enable broadband and wireless providers to continually enhance their network capacity, speed and coverage to advance the free flow of information that empowers the lives of millions of people daily. The Mixed-Signal Optics technology at the heart of our broadband transmission products is shared with our fiber optic gyros and military communications links to provide the aerospace and defense markets state-of-the-art systems that keep us safe in an increasingly unpredictable world. EMCORE’s performance-leading optical components and systems serve a broad array of applications including cable television, fiber-to-the-premise networks, telecommunications, wireless infrastructure, satellite RF fiber links, navigation systems and military communications. EMCORE has fully vertically-integrated manufacturing capability through its world-class Indium Phosphide (InP) wafer fabrication facility at our headquarters in Alhambra, California and is ISO 9001 certified in Alhambra, and at our facilities in Warminster, Pennsylvania and China. For more information, please visit www.emcore.com.

Forward-looking statements:
The information provided herein may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include statements regarding EMCORE’s plans, strategies, business prospects, growth opportunities, changes and trends in our business and expansion into new markets. These forward-looking statements are based on management’s current expectations, estimates, forecasts and projections about EMCORE and are subject to risks and uncertainties that could cause actual results and events to differ materially from those stated in the forward-looking statements, including without limitation, the following: (a) the rapidly evolving markets for EMCORE’s products and uncertainty regarding the development of these markets; (b) EMCORE’s historical dependence on sales to a limited number of customers and fluctuations in the mix of products and customers in any period; (c) delays and other difficulties in commercializing new products; (d) the failure of new products: (i) to perform as expected without material defects, (ii) to be manufactured at acceptable volumes, yields, and cost, (iii) to be qualified and accepted by our customers, and (iv) to successfully compete with products offered by our competitors; (e) uncertainties concerning the availability and cost of commodity materials and specialized product components that we do not make internally; (f) actions by competitors; and (g) other risks and uncertainties discussed under Item 1A – Risk Factors in our Annual Report on Form 10-K for the fiscal year ended September 30, 2015, as updated by our subsequent periodic reports. Forward-looking statements contained in this press release are made only as of the date hereof, and EMCORE undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

EMCORE Corporation

David Faulkner 
Vice President and General Manager, Aerospace & Defense
(626) 293-3698
David_Faulkner@emcore.com

Media
Joel Counter
Manager, Corporate & Marketing Communications
(626) 999-7017
media@emcore.com

Investor
Erica Mannion
Sapphire Investor Relations, LLC 
(617) 542-6180 
investor@emcore.com

$ZFGN Announces Positive Topline Phase 1 Data for ZGN-1061

– Clinical Trial Shows Weight Loss Trends of Up to One Pound Per Week and an Early Favorable Safety and Tolerability Profile –

– Improvements in Metabolic Parameters and Trends for Weight Loss Supportive of Drug Effect –

– Results Support Advancement to Phase 2 Clinical Trial in Patients with Type 2 Diabetes in the Second Half of This Year –

-Company to Host Conference Call at 4:30 PM Today –

BOSTON, May 04, 2017 — Zafgen, Inc. (Nasdaq:ZFGN) today announced positive topline data from its Phase 1 clinical trial of ZGN-1061, the Company’s second generation MetAP2 inhibitor. ZGN-1061 demonstrated rapid drug absorption and clearance in line with pre-specified criteria established for the molecule, and was well-tolerated and safe, with no evidence of prothrombotic effects. Patients in the clinical trial experienced mean weight loss of up to approximately one pound per week.

“The results from this clinical trial mark an important first step in the clinical development of ZGN-1061, which has been optimized to improve glycemic control and body weight, with a favorable safety profile,” said Thomas Hughes, Ph.D., President and Chief Executive Officer of Zafgen. “The safety data and the early efficacy signals support the further development of this compound, and we plan to advance ZGN-1061 into a Phase 2 clinical trial in the second half of this year in patients with type 2 diabetes who are overweight or obese.”

The Phase 1 clinical trial included a single ascending dose (SAD) phase, which enrolled healthy volunteers, and a multiple ascending dose (MAD) phase, which evaluated twice-weekly administration of ZGN-1061 in overweight or obese patients over four weeks. The SAD phase was comprised of six dosing cohorts ranging from 0.2 mg to 4.8 mg and the MAD phase was comprised of three dosing cohorts of 0.2 mg, 0.6 mg and 1.8 mg. The SAD phase included 39 volunteers (ZGN-1061 N=28, placebo N=11), 90% male and average body mass index (BMI) of 26 kg/m²; and the MAD phase included 29 patients (ZGN-1061 N=22, placebo N=7), 76% male and average BMI of 33 kg/m². Patients in the MAD phase were domiciled while receiving treatment and were subjected to inpatient safety monitoring for most of the clinical trial’s 28-day duration.

Topline Data:

ZGN-1061 was safe and well-tolerated, with no serious adverse events (SAEs), and no severe adverse events (AEs). There were no AEs leading to early withdrawal from the clinical trial. All AEs were of mild intensity in the MAD phase except one (toothache). The most common side effects were mild gastrointestinal issues, which were comparable between the ZGN-1061 and placebo groups, headache and procedural related irritation.

There was no prothrombotic effect observed with ZGN-1061. No treatment emergent venous thromboembolisms (VTEs), no clinically meaningful D-dimer elevations indicative of thrombosis and no elevations in mean D-dimer levels were observed in the dosing groups compared to baseline or placebo.  There were no clinically significant changes in coagulation laboratory parameters or other key biomarkers of interest, including von Willebrand factor, soluble thrombomodulin and plasminogen activator inhibitor-1.

On average, patients treated with ZGN-1061 for four weeks lost weight relative to placebo-treated patients (-4.6 lbs, -2.2 lbs, and -3.8 lbs for 0.2 mg, 0.6 mg, and 1.8 mg, respectively vs. -0.51 lbs for placebo), with trends for improvements observed in waist circumference, food intake, low density lipoprotein-cholesterol, C-reactive protein, adiponectin and leptin.

ZGN-1061 demonstrated rapid drug exposure and clearance for all dose levels, in line with prospectively established criteria. Effective concentrations of drug were reached in circulation based on measurements of drug binding to the MetAP2 target enzyme.

“The data from this clinical trial provide a first view of the therapeutic potential of ZGN-1061 and its early favorable tolerability and safety profile,” stated Dr. Louis Aronne, the Sanford I. Weill Professor of Metabolic Research and a professor of clinical medicine at Weill Cornell Medicine.^[i] “These early data provide a strong rationale for continued development of this promising molecule for the twin public health concerns of type 2 diabetes and obesity.”

“The compound showed a promising efficacy signal on weight loss and improvement in metabolic parameters, which is consistent with what we would expect to see with MetAP2 inhibition,” said Dennis Kim, M.D., Chief Medical Officer of Zafgen. “In addition, ZGN-1061 demonstrated more favorable pharmacokinetic and safety attributes compared to first generation MetAP2 inhibitors, with no clinically meaningful impact on sleep and no evidence of elevated thrombotic risk in this small clinical trial.”

Conference Call Information

Zafgen will host an investor conference call today, May 4, 2017 at 4:30 p.m., Eastern Time, to discuss the Phase 1 clinical trial data and provide a financial update. This call will replace the Company’s usual quarterly earnings call. Investors and other interested parties may participate by dialing (844) 824-7428 in the United States or (973) 500-2177 outside the United States and referencing conference ID number 13508906. The call will also be webcast live on the Company’s website at http://ir.zafgen.com/events.cfm. A replay of this conference call will be available beginning at 11:30 p.m. ET on May 4, 2017 through May 11, 2017 by dialing (855) 859-2056 in the United States or (404) 537-3406 outside the United States. To access the replay please provide Conference ID number 13508906.

About ZGN-1061

ZGN-1061 is a fumagillin-class, injectable small molecule second generation MetAP2 inhibitor that was advanced into development due to its unique properties that maximize impact on metabolic parameters relevant to the treatment of type 2 diabetes and other related metabolic disorders. In pre-clinical studies, ZGN-1061 has demonstrated promising efficacy in animal models of type 2 diabetes and obesity, with an improved pharmacokinetic profile and safety margin relative to previous molecules in the MetAP2 class. As demonstrated clinically for MetAP2 inhibitors, ZGN-1061 is anticipated to improve glycemic control while also helping to restore balance to fat metabolism, enabling calories to once again be used as a productive energy source, leading to improved metabolic control and long-term weight loss. Zafgen recently completed its first Phase 1 clinical trial of ZGN-1061, and is planning to advance the compound to Phase 2 clinical testing in patients with type 2 diabetes who are overweight or obese. Zafgen holds exclusive worldwide rights for the development and commercialization of ZGN-1061.

About Zafgen

Zafgen (Nasdaq:ZFGN) is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic diseases including type 2 diabetes and obesity. Zafgen is focused on developing novel therapeutics that treat the underlying biological mechanisms of metabolic diseases through the MetAP2 pathway. Zafgen has pioneered the study of MetAP2 inhibitors in both common and rare forms of obesity, and in patients affected by type 2 diabetes. Zafgen’s lead product candidate is ZGN-1061, which is a novel, first-in-class, subcutaneous injection. Zafgen aspires to improve the lives of patients through targeted treatments and has assembled a team accomplished in bringing therapies to patients affected by metabolic diseases.

Safe Harbor Statement

Various statements in this release concerning Zafgen’s future expectations, plans and prospects, including without limitation, Zafgen’s expectations regarding the use of ZGN-1061 and other MetAP2 inhibitors as treatments for metabolic diseases including type 2 diabetes and obesity, ZGN-1061’s improved safety margin, including as it relates to pro-thrombotic characteristics compared to first generation MetAP2 inhibitors, such as beloranib, and Zafgen’s expectations with respect to the timing and success of its pre-clinical studies and clinical trials of ZGN-1061 and its other product candidates may constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements can be identified by terminology such as “anticipate,” “believe,” “could,” “could increase the likelihood,” “estimate,” “expect,” “intend,” “is planned,” “may,” “should,” “will,” “will enable,” “would be expected,” “look forward,” “may provide,” “would” or similar terms, variations of such terms or the negative of those terms. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Zafgen’s ability to successfully demonstrate the efficacy and safety of ZGN-1061 and its other product candidates and to differentiate ZGN-1061 and its other product candidates from first generation MetAP2 inhibitors, such as beloranib, the pre-clinical and clinical results for ZGN-1061 and its other product candidates, which may not support further development and marketing approval, actions of regulatory agencies, which may affect the initiation, timing and progress of pre-clinical studies and clinical trials of its product candidates, Zafgen’s ability to obtain, maintain and protect its intellectual property, Zafgen’s ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties, competition from others developing products for similar uses, Zafgen’s ability to manage operating expenses, Zafgen’s ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives when needed, Zafgen’s dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled “Risk Factors” in Zafgen’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in Zafgen’s subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Zafgen’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Zafgen explicitly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

___________________________
^[i] Dr. Aronne is a Zafgen stockholder and member of the Company’s Clinical Advisory Board.

Media/Investor Relations Contact:
Zafgen, Inc.
Patricia Allen
Chief Financial Officer
617-648-9792

Argot Partners
Investor Relations
Laura Perry 
212-600-1902
laura@argotpartners.com

Spectrum Science
Media Relations
Michelle Strier
202-587-2582
mstrier@spectrumscience.com

$AMMA Signs Sensational New Prospects to Multi-Fight Agreements in the Northwest

Alliance MMA, Inc. (“Alliance MMA” or the “Company”) (NASDAQ:AMMA), a professional mixed martial arts (MMA) company that brings together leading regional productions to build the next generation of MMA champions, announced today signings of several fighters by Pacific Northwest promotion Combat Games MMA (COGA).

“Alliance MMA’s mission to identify and cultivate the next generation of champions, and that starts with signing exclusive fight deals with the most promising prospects,” said Robert Haydak, President of Alliance MMA. “Combat Games is following that strategy by quickly establishing a remarkable roster with enormous fighter talent.”

Joey Pierotti (27), from Enumclaw, Washington, Miranda Granger (27), from Snohomish, Washington, and Nathan Stolen (24), from Aberdeen, Washington have all signed multi-fight deals with COGA.

“I couldn’t be more happy or proud to have signed three of Washington’s next big superstars,” said Combat Games General Manager Joe DeRobbio. “Joey, Miranda, Nathan, their families and their coaches are all quality individuals, positive contributors to the sport of MMA and the communities they serve. We look forward to shepherding their journey to the world’s biggest stage. This is just the beginning as COGA continues to expand its regional footprint into new markets. I’m passionately dedicated to achieving my vision of building the best possible showcase for these young athletes.”

Joey “Mama’s Boy” Pierotti is an undefeated welterweight with a record of 5-0. A Port of Seattle firefighter by day and MMA fighter by night, Pierotti is scheduled to face Andy Nigretto for the Combat Games welterweight title on May 20^th at COGA 55 – Rumble On The Ridge at the Snoqualmie Casino.

Miranda “Danger” Granger is also undefeated, and someone who has alternated between MMA and kickboxing throughout her first 10 fights. Granger has held several belts thus far in her career including the AX Fighting Championships Amateur World Kickboxing Title and COGA Amateur Strawweight Title. Granger is a life-long martial artist training since the age of four. She takes pride in being a part of the rise of Women’s MMA in recent years.

Nathan “Superman” Stolen is the current COGA featherweight champion who is coming off a third round submission victory (Kimura) over Carson Frei at COGA 54. Stolen has displayed a tremendous ability to get fans out of their seats by finishing all of his pro bouts to date. At just 24 years of age, Stolen has already proven to be a member of the elite fighters in the Pacific Northwest region.

Tickets for COGA 55 – Rumble On The Ridge on Saturday, May 20^th, are on sale and can be purchased at Cagetix.com/COGA.

About Alliance MMA, Inc.

Alliance MMA (NASDAQ: AMMA) is a professional mixed martial arts company that brings together the best regional productions. Alliance MMA’s mission is to identify and cultivate the next generation of fighters and champions for the Ultimate Fighting Championship (UFC) and other premier MMA promotions.

With some of the world’s leading MMA promotions under the Alliance MMA umbrella, the organization aims eventually to host in excess of 125 events per year, showcasing more than 1,000 fighters. Alliance MMA is also dedicated to generating live original sports media content, attracting an international fan base, and securing major brand sponsorship revenue for live MMA events, digital media, and Alliance MMA fighters.

MMA is the world’s fastest growing sport with worldwide fans of approximately 300 million according to sports marketing research firm Repucom. MMA is a full contact sport that allows a wide range of fighting techniques, including striking and grappling from various martial arts and disciplines including Boxing, Wrestling, Brazilian Jiu Jitsu, Karate and Muay Thai. Professional MMA fights are legal and regulated by state athletic commissions in all 50 states.

Alliance MMA, Inc. was incorporated in 2015 for the purpose of acquiring businesses that engage in the promotion of mixed martial arts (MMA) events. In 2016, the company completed an initial public offering that culminated in a listing on the NASDAQ stock exchange. Alliance MMA is the only mixed martial arts promotion company that is publicly-traded.

For more information visit, www.alliancemma.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. These statements relate to anticipated future events, future results of operations or future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “might,” “will,” “should,” “intends,” “expects,” “plans,” “goals,” “projects,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” or “continue” or the negative of these terms or other comparable terminology. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, those discussed under the heading “Risk Factors” in our registration statement on Form S-1 (Registration No. 333-213166) declared effective by the Securities and Exchange Commission on September 2, 2016. Alliance MMA encourages you to review other factors that may affect its future results in Alliance MMA’s registration statement and in its other filings with the Securities and Exchange Commission.

$CDNA Achieves Significant Milestone Towards CMS Coverage for AlloSure

BRISBANE, Calif., May 04, 2017 — CareDx, Inc. (NASDAQ:CDNA) announces that Palmetto GBA has released a draft local coverage determination (LCD) for AlloSure. AlloSure is the first and only non-invasive test that uses donor derived cell free DNA as a biomarker to directly measure allograft injury and identify the probability of active rejection.

“This marks an important milestone in making AlloSure available to kidney transplant patients,” said Peter Maag, Chief Executive Officer at CareDx. “We are tracking against a commercial launch of AlloSure later in 2017 following the completion of reimbursement discussions. The draft LCD release underscores our leadership position in partnering with the transplant community on novel diagnostic solutions to improve patient management and long-term outcomes.”

The draft local coverage decision was issued following completion of the MolDx (Molecular Diagnostics) Technical Assessment process by Palmetto GBA. During the technical assessment process, subject matter experts and the MolDx team determine if an assay demonstrates clinical utility and fulfills the Centers for Medicare & Medicaid Services (CMS) ‘reasonable and necessary’ criteria. In order to receive favorable review results, the assay must also meet analytical and clinical validity standards.

CMS has awarded Palmetto GBA with the administration of the Molecular Diagnostics Program. The MolDx group at Palmetto has accumulated a wealth of knowledge on the clinical use of high value diagnostics. Other Medicare Administrative Contractors that participate in the Palmetto GBA MolDX Program are expected to also issue local coverage determinations for AlloSure in the near future.

There were over 19,000 kidney transplants in 2016 in the US, but about 20% will experience rejection in the first five years. With a long waiting list to receive a kidney transplant, graft loss is devastating.  “Once kidney disease patients receive a transplant, their quality of life significantly improves,” said Jim Gleason, TRIO National President. “Better diagnostics that support the patient management and rejection detection are needed. The transplant community looks forward to having the AlloSure test available to support those long-term post-transplant life benefits.”

The draft LCD can be found online here: https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=37265&ContrId=381&ver=6&ContrVer=1&CntrctrSelected=381*1&Cntrctr=381&name=&DocType=AllProposed&s=34%7c48%7c53%7c58&bc=AggAAAQAAAAAAA%3d%3d&

About CareDx
CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, non-invasive diagnostic surveillance solutions for transplant recipients. The Company has commercialized AlloMap®, a gene expression test that aids clinicians in identifying heart transplant recipients.  CareDx is pursuing the development of additional products for post-transplant monitoring of other solid organs that use a variety of technologies, including next generation sequencing, to detect donor-derived cell-free DNA to monitor the health of organs after transplantation.

CareDx, with its presence through Olerup, also develops, manufactures, markets and sells high quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs.

For more information, please visit: www.CareDx.com.

Forward Looking Statements
This press release contains forward-looking statements about our business, research, development and commercialization efforts including, but not limited to the development, commercialization, utility, performance and adoption of AlloSure. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risk associated with successful research, development and planned commercialization of our technologies, that are described in our filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2015 filed by us with the SEC on March 29, 2016 and the Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2016 filed by us with the SEC on November 14, 2016.  Any of these may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

Contact
Sasha King, Head of Marketing
T: +1 415-287-2393
E: sking@caredx.com

$AMMA Consummates Atlanta Promotion Deal

Alliance MMA, Inc. (“Alliance MMA” or the “Company”) (NASDAQ:AMMA), a professional mixed martial arts (MMA) company that brings together the best regional productions building the next generation of MMA champions, announced today it has acquired the assets of National Fighting Championship (NFC), which produces professional regional MMA events throughout Georgia and South Carolina.

“We are effectively and systematically continuing to execute our strategy of aggressively acquiring leading regional MMA promotions across the country,” said Robert Haydak, President of Alliance MMA. “The addition of NFC to the Alliance MMA enterprise clearly validates the ongoing success of our business model. Their documented experience in producing outstanding MMA events, and the fact that they have established a solid brand name in Atlanta, one of our remaining targeted top 20 national media markets, makes NFC an ideal fit for Alliance MMA.”

In 2002, at the age of 26, David Oblas formed Undisputed Productions, LLC and became the youngest promoter in the history of fight promotion in Georgia – he is currently the longest running MMA promoter in the state. In 2007, he rebranded Undisputed Productions to National Fighting Championship (NFC). In 2017, Mr. Oblas acquired US Freedom Fighter Championship (USFFC), based in South Carolina, and after rebranding it with the NFC name, will continue to promote MMA events in various South Carolina markets. Undisputed Productions and NFC have promoted a combined total of more than 100 events since 2002, and NFC plans to continue its expansion throughout Georgia and South Carolina.

To date, NFC has promoted fights at a number of venues in Atlanta, and currently produces regional MMA events at Center Stage in Atlanta, Infinite Energy Arena in Duluth, GA, Electric Cowboy in Kennesaw, GA, and the TD Convention Center in Greenville, SC. On July 22 of this year, NFC will host an all-day event at Infinite Energy Arena in Duluth, GA to celebrate its 15-year anniversary, and later this year will promote NFC 100.

“I started promoting professional MMA events because I’m the biggest fan of the sport. After attending shows for years as a member of the Georgia Athletic & Entertainment Commission, I believed I could do better,” said Oblas. “Everything I’ve done since 2002 has been with the mindset of making NFC the best possible experience for the fighters and fans. Joining Alliance MMA is no different. Alliance MMA is providing me with the opportunity to continue delivering the very best regional MMA events in the Southeast to fighters and fans.”

NFC will be the 9^th regional MMA promotion operating under the Alliance MMA umbrella. The Company also promotes regional MMA events through New Jersey-based Cage Fury Fighting Championship (CFFC), Washington-based Combat Games MMA (COGA), Illinois-based Hoosier Fight Club (HFC), Tennessee-based V3 Fights, Maryland-based Shogun Fights, Ohio-based Iron Tiger Fight Series (IT Fight Series), Florida-based Fight Time Promotions, as well as a San Diego-based promotion under the guidance of MMA luminary Eric Del Fierro.

About Alliance MMA, Inc.

Alliance MMA (NASDAQ:AMMA) is a professional mixed martial arts (MMA) company that brings together the best regional productions. Alliance MMA’s mission is to identify and cultivate the next generation of fighters and champions for the Ultimate Fighting Championship (UFC) and other premier MMA promotions.

With some of the world’s leading MMA promotions under the Alliance MMA umbrella, the organization aims eventually to host in excess of 125 events per year, showcasing more than 1,000 fighters. Alliance MMA is also dedicated to generating live original sports media content, attracting an international fan base, and securing major brand sponsorship revenue for live MMA events, digital media, and Alliance MMA fighters.

MMA is the world’s fastest growing sport with worldwide fans of approximately 300 million according to sports marketing research firm Repucom. MMA is a full contact sport that allows a wide range of fighting techniques, including striking and grappling from various martial arts and disciplines including Boxing, Wrestling, Brazilian Jiu Jitsu, Karate and Muay Thai. Professional MMA fights are legal and regulated by state athletic commissions in all 50 states.

Alliance MMA, Inc. was incorporated in 2015 for the purpose of acquiring businesses that engage in the promotion of mixed martial arts (MMA) events. In 2016, the company completed an initial public offering that culminated in a listing on the NASDAQ stock exchange. Alliance MMA is the only mixed martial arts promotion company that is publicly-traded.

For more information visit, www.alliancemma.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. These statements relate to anticipated future events, future results of operations or future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “might,” “will,” “should,” “intends,” “expects,” “plans,” “goals,” “projects,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” or “continue” or the negative of these terms or other comparable terminology. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, those discussed under the heading “Risk Factors” in our registration statement on Form S-1 (Registration No. 333-213166) declared effective by the Securities and Exchange Commission on September 2, 2016. Alliance MMA encourages you to review other factors that may affect its future results in Alliance MMA’s registration statement and in its other filings with the Securities and Exchange Commission.

$LNTH Public Secondary Offering by Selling Stockholders, 3M Shares of Common Stock

Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ:LNTH), today announced an agreement to sell 3,000,000 shares of its common stock to be offered by certain of its existing stockholders (the “Selling Stockholders”), pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the “SEC”) on Form S-3. The Company will not receive any proceeds from the sale of shares by the Selling Stockholders. Credit Suisse Securities will act as underwriter for the offering.

A shelf registration statement (including a prospectus) relating to the offering of common stock was filed with the SEC on December 12, 2016 (and became effective on January 4, 2017). Before you invest, you should read the prospectus included in the registration statement and the documents incorporated by reference therein as well as the prospectus supplement related to this offering. You may obtain these documents for free by visiting EDGAR on the SEC website at www.sec.gov. When available, copies of the prospectus supplement and accompanying prospectus related to the offering may also be obtained by contacting Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, One Madison Avenue, New York, New York, 10010, or by calling (800) 221-1037, or by emailing newyork.prospectus@credit-suisse.com.

The offering of these securities will be made only by means of a prospectus supplement and the accompanying prospectus.

This release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer to buy the securities may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to notice of its acceptance given after the effective date of the shelf registration statement.

About Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc.
Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. LMI provides a broad portfolio of products, which are primarily used for the diagnosis of cardiovascular diseases. LMI’s key products include the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. The Company is headquartered in North Billerica, Massachusetts with offices in Puerto Rico and Canada.

Safe Harbor
This press release includes statements that express our opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results and therefore are, or may be deemed to be, “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the offering. These forward-looking statements can generally be identified by the use of forward-looking terminology, including the terms “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “should,” “could,” “predicts,” “targets,” “hopes” or, in each case, their negatives or other variations or comparable terminology. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future, including risks and uncertainties relating to the consummation of the proposed offering by the Selling Stockholders and the risks identified, or incorporated by reference, in the prospectus supplement or accompanying prospectus.

Lantheus Holdings, Inc.
Corporate Communications:
Meara Murphy, 978-671-8508
or
Investor Relations:
Gary F. Santo, Jr., 978-671-8960